{"id":40076,"date":"2021-11-10T18:15:48","date_gmt":"2021-11-10T17:15:48","guid":{"rendered":"https:\/\/www.crct-inserm.fr\/v2\/?page_id=40076"},"modified":"2024-01-08T14:40:38","modified_gmt":"2024-01-08T13:40:38","slug":"igaald","status":"publish","type":"page","link":"https:\/\/www.crct-inserm.fr\/igaald\/","title":{"rendered":"IGAALD"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”a00720d8-8e3f-4b20-83b7-6d54485f541c” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”694d3d5d-3e0a-4cd1-b2ba-4eea0d99d5b4″ background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/11\/inserm_54928_-LeucemieAigueMyeloide_IAU-1.png” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”8292df69-9d3c-4423-ab4f-a4755f6c1135″ width_tablet=”85%” width_phone=”95%” width_last_edited=”on|phone” custom_padding_last_edited=”off|desktop” global_colors_info=”{}”]<\/p>\n

\u00c9quipe
Eric Delabesse<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ header_2_font=”Open Sans||||||||” global_colors_info=”{}”]<\/p>\n

IGAALD : <\/strong><\/h2>\n

Impact des alt\u00e9rations g\u00e9n\u00e9tiques sur le d\u00e9veloppement <\/strong><\/h2>\n

des leuc\u00e9mies aigu\u00ebs<\/strong><\/h2>\n

 <\/p>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” width=”50%” disabled=”on” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/LOGO-TOUCAN-Horizontal.png” title_text=”LOGO-TOUCAN-Horizontal” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font_size=”22px” global_colors_info=”{}”]<\/p>\n

Le laboratoire d\u2019Excellence Toulouse Cancer est un projet qui vise \u00e0 comprendre les m\u00e9canismes de r\u00e9sistance et de rechute dans les cancers.<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|on” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”rgba(43,135,218,0) 50%|#f2efef 50%” background_color_gradient_start=”rgba(43,135,218,0)” background_color_gradient_start_position=”50%” background_color_gradient_end=”#f2efef” background_color_gradient_end_position=”0%” custom_padding=”0px|||||” disabled=”on” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=FkQuawiGWUw” image_src=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/video.jpg” _builder_version=”4.16″ _module_preset=”default” width=”80%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” custom_padding=”0px||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

Les sp\u00e9cificit\u00e9s
<\/strong>de notre axe de recherche<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

 <\/p>\n

\"\"<\/a>Les leuc\u00e9mies aigu\u00ebs sont des cancers de la moelle osseuse associ\u00e9s \u00e0 un mauvais pronostic, principalement sporadiques, certaines ont une origine g\u00e9n\u00e9tique. Le d\u00e9veloppement de ces cancers fait suite \u00e0 l\u2019acquisition successive de mutations, (g\u00e9n\u00e9ralement entre 1 \u00e0 5).<\/p>\n

Nous analysons les m\u00e9canismes biologiques par lesquels les mutations des g\u00e8nes centraux de l\u2019h\u00e9matopo\u00ef\u00e8se (principalement PAX5<\/em> dans la diff\u00e9renciation B, GATA2<\/em> dans la diff\u00e9renciation my\u00e9lo\u00efde et USP7 et CHK1 acteurs du cycle cellulaire) reprogramment les prog\u00e9niteurs normaux pour \u00e9tablir un \u00e9tat pr\u00e9-leuc\u00e9mique et initier cette transformation leuc\u00e9mique. Notre \u00e9quipe utilise une approche multidisciplinaire sur des \u00e9chantillons de patients et des mod\u00e8les murins, utilisant de la mutagen\u00e8se par technologie CRISPR-Cas9, des tests fonctionnels ex<\/em> vivo<\/em> et in vivo<\/em>, de la cytom\u00e9trie en flux, des analyses du transcriptome et des mutations (par s\u00e9quen\u00e7age de nouvelle g\u00e9n\u00e9ration) et du criblage \u00e0 haut d\u00e9bit de m\u00e9dicaments.<\/p>\n

Cette approche combin\u00e9e nous permet d\u2019\u00e9tudier le d\u00e9veloppement h\u00e9matopo\u00ef\u00e9tique normal et la biologie des cellules souches h\u00e9matopo\u00ef\u00e9tiques ainsi que la reprogrammation oncog\u00e9nique et le processus oncog\u00e9nique induits par ces mutants.<\/p>\n

Ces travaux s\u2019int\u00e8gre ainsi dans une recherche fondamentale et translationnelle, ayant pour perspective l\u2019identification de nouveaux agents th\u00e9rapeutiques am\u00e9liorant le traitement de la leuc\u00e9mie aigu\u00eb, en particulier le ciblage des cellules souches leuc\u00e9miques.<\/p>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Recherche clinique<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”5px||5px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Syndromes my\u00e9lodysplasiques<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Leuc\u00e9mies Aigu\u00ebs My\u00e9lo\u00efdes B<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

Facteur de transcription GATA2<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

mutations germinales<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” text_font=”Open Sans|700|||||||” text_orientation=”center” custom_margin=”||15px||false|false” custom_padding=”15px||15px||false|false” border_color_bottom=”#F19532″ border_width_left=”5px” border_color_left=”#F19532″ global_colors_info=”{}”]<\/p>\n

registre national<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

DES PROJETS<\/strong>
DE RECHERCHE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row use_custom_gutter=”on” gutter_width=”2″ _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_blog fullwidth=”off” include_categories=”344″ use_manual_excerpt=”off” show_more=”on” show_author=”off” show_date=”off” show_categories=”off” masonry_tile_background_color=”#f2efef” _builder_version=”4.16″ _module_preset=”default” header_level=”h3″ header_font=”|800|||||||” header_font_size=”20px” body_font_size=”20px” read_more_text_color=”#5EC7ED” read_more_font_size=”20px” read_more_line_height=”3em” background_enable_color=”off” border_width_all=”0px” global_colors_info=”{}”][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” custom_padding=”||0px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES FOCUS<\/strong>
DE L\u2019\u00c9QUIPE<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” use_background_color_gradient=”on” background_color_gradient_stops=”#ffffff 50%|rgba(174,227,246,0) 50%” background_color_gradient_overlays_image=”on” background_color_gradient_start=”#ffffff” background_color_gradient_start_position=”50%” background_color_gradient_end=”rgba(174,227,246,0)” background_color_gradient_end_position=”0%” background_image=”https:\/\/www.crct-inserm.fr\/wp-content\/uploads\/2021\/03\/Filets-bleu-actu.png” background_size=”contain” background_position=”bottom_center” custom_padding=”0px|||||” saved_tabs=”all” global_colors_info=”{}”][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” header_font_size_tablet=”” header_font_size_phone=”” header_font_size_last_edited=”on|desktop” header_2_font_size_tablet=”” header_2_font_size_phone=”” header_2_font_size_last_edited=”on|desktop” header_4_font_size_tablet=”” header_4_font_size_phone=”” header_4_font_size_last_edited=”on|desktop” global_colors_info=”{}”]<\/p>\n

D\u00e9couvrir<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1019″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” _builder_version=”4.16″ _module_preset=”412cf9f9-c22e-468d-92e3-f93d454642a9″ header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_color_all_image=”#ffffff” border_width_bottom_image=”15px” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-3px||false|false” global_colors_info=”{}”]<\/p>\n

Comprendre<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1196,1216″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” show_image_tablet=”” show_image_phone=”” show_image_last_edited=”on|phone” disabled_on=”off|off|off” _builder_version=”4.19.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”4ae3b26e-eab0-4b6f-bd7b-05f173fca79b” custom_margin=”||-4px||false|false” global_colors_info=”{}”]<\/p>\n

Participer<\/h4>\n

[\/et_pb_text][et_pb_post_slider posts_number=”5″ include_categories=”1283,1319″ show_arrows=”off” use_manual_excerpt=”off” excerpt_length=”0″ show_meta=”off” image_placement=”top” use_bg_overlay=”off” use_text_overlay=”off” dot_nav_custom_color=”#5EC7ED” disabled_on=”off|off|off” _builder_version=”4.21.0″ _module_preset=”default” header_font=”Open Sans|600|||||||” header_text_color=”#5EC7ED” header_font_size=”20px” header_line_height=”1.2em” body_font=”Open Sans||||||||” body_text_align=”left” body_text_color=”#505659″ body_font_size=”18px” background_color=”#FFFFFF” custom_button=”on” button_text_size=”18px” button_bg_color=”#5EC7ED” button_border_width=”0px” button_border_radius=”0px” button_use_icon=”off” button_alignment=”center” button_custom_margin=”20px||0px||false|false” button_custom_padding=”10px|50px|10px|50px|true|true” custom_padding=”0px|||||” header_font_size_tablet=”” header_font_size_phone=”22px” header_font_size_last_edited=”on|phone” body_font_size_tablet=”” body_font_size_phone=”18px” body_font_size_last_edited=”on|phone” border_width_bottom_image=”15px” border_color_bottom_image=”#ffffff” text_shadow_style=”preset4″ text_shadow_vertical_length=”0em” global_colors_info=”{}”][\/et_pb_post_slider][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”off|off|off” _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

En live<\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][et_pb_code _builder_version=”4.22.1″ _module_preset=”default” max_width=”800px” module_alignment=”center” global_colors_info=”{}”]\n\n

\n\t\n \n
\n \n
\n

\n DelabesseTeam<\/span>\n <\/span>\n Suivre<\/span>\n \n <\/path><\/svg>14<\/span>\n <\/path><\/svg>44<\/span>\n <\/span>\n <\/p>\n <\/div>\n

\n
\n <\/path><\/svg> <\/div>\n \"DelabesseTeam\"\n <\/div>\n <\/a>\n<\/div>\n\n
\n \n
\n\n
\n <\/path><\/svg>Retweeter sur Twitter<\/span><\/a>\n DelabesseTeam Retweet\u00e9<\/a>\n<\/div>\n\n
\n
\n \n \"LargeaudLaet;\n <\/a>\n \n Laetitia Largeaud<\/a>\n @LargeaudLaet<\/a>\n \n \t\t ·<\/span>\n\t
\n 3 F\u00e9v 2023 1621602332042461185<\/span><\/a>\n <\/div>\n <\/div>\n
\n <\/path><\/svg> <\/div>\n <\/div>\n\n
\n \t\t\t\t

Happy to share our work about somatic alterations in GATA2 deficiency. https:\/\/haematologica.org\/article\/view\/haematol.2022.282250 Thanks to all members of French\/Belgium GATA2 Group @marlene_pasquet and collaborators @MatthewCollin<\/p>\n\t\t\t\t\t\t\n \n\t \n \n <\/div>\n \n\t\n

\n \n <\/path><\/g><\/svg> R\u00e9pondre sur Twitter 1621602332042461185<\/span>\n <\/a>\n\n \n <\/path><\/svg> Retweeter sur Twitter 1621602332042461185<\/span>\n 6<\/span>\n <\/a>\n\n \n <\/path><\/g><\/svg> J\u2019aime sur Twitter 1621602332042461185<\/span>\n 16<\/span>\n <\/a>\n\n \n Twitter<\/span>\n 1621602332042461185<\/span>\n <\/a>\n \n\t<\/div>\n\n\t<\/div>\n\n <\/div>\n\n Voir plus<\/span><\/a>\n\n<\/span>\n<\/div>\n[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” background_color=”#f2efef” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

PRODUCTIONS SCIENTIFIQUES<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_toggle title=”PUBLICATIONS 2024″ open=”on” open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t9RREECEZ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2024<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 40076<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2023″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.22.1″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t9RREECEZ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2023<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 40076<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-fbf1f3444799a6e2552bd7c411b9049f%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22F3UH3YAC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Tamburini%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-26%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ETamburini%2C%20Jerome%2C%20Sarah%20Mouche%2C%20Clement%20Larrue%2C%20Nicolas%20Duployez%2C%20Audrey%20Bidet%2C%20Auriane%20Salotti%2C%20Pierre%20Hirsch%2C%20et%20al.%20%26%23x201C%3BVery%20Short%20Insertions%20in%20the%20FLT3%20Gene%20Are%20of%20Therapeutic%20Significance%20in%20Acute%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%207%2C%20no.%2024%20%28December%2026%2C%202023%29%3A%207576%26%23x2013%3B80.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2023011916%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2023011916%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Very%20short%20insertions%20in%20the%20FLT3%20gene%20are%20of%20therapeutic%20significance%20in%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Tamburini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Mouche%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Clement%22%2C%22lastName%22%3A%22Larrue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Duployez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Auriane%22%2C%22lastName%22%3A%22Salotti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucie%22%2C%22lastName%22%3A%22Rigolot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvain%22%2C%22lastName%22%3A%22Carras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Templ%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrizia%22%2C%22lastName%22%3A%22Favale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Flandrin-Gresta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Le%20Bris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Alary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Mauvieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22Tondeur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Delhommeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sujobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Kosmider%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-12-26%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2023011916%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-12-20T13%3A04%3A35Z%22%7D%7D%2C%7B%22key%22%3A%22NV8VJWPE%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Faguer%20et%20al.%22%2C%22parsedDate%22%3A%222023-12-22%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFaguer%2C%20Stanislas%2C%20Eric%20Delabesse%2C%20Carle%20Paul%2C%20and%20Marl%26%23xE8%3Bne%20Pasquet.%20%26%23x201C%3BIL-4R%26%23x3B1%3B%20Inhibition%20for%20Severe%20%26%23x2018%3BEosinophilic%20Gastroenteritis%2C%20Allergy%2C%20and%20Anaphylaxis%26%23x2019%3B%20Syndrome%20Due%20to%20a%20Gain-of-Function%20Variant%20in%20STAT6.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Clinical%20Immunology%3C%5C%2Fi%3E%2044%2C%20no.%201%20%28December%2022%2C%202023%29%3A%2029.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10875-023-01639-9%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10875-023-01639-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22IL-4R%5Cu03b1%20Inhibition%20for%20Severe%20%5C%22Eosinophilic%20Gastroenteritis%2C%20Allergy%2C%20and%20Anaphylaxis%5C%22%20Syndrome%20due%20to%20a%20Gain-of-Function%20Variant%20in%20STAT6%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanislas%22%2C%22lastName%22%3A%22Faguer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carle%22%2C%22lastName%22%3A%22Paul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Pasquet%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-12-22%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10875-023-01639-9%22%2C%22ISSN%22%3A%221573-2592%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-12-29T18%3A15%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22SB2HWP7V%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Darlington%20et%20al.%22%2C%22parsedDate%22%3A%222023-09%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDarlington%2C%20Meryl%2C%20Pierre%20Sujobert%2C%20Olivier%20Kosmider%2C%20Damien%20Luque%20Paz%2C%20Sophie%20Kaltenbach%2C%20Martin%20Figeac%2C%20Sandrine%20Hayette%2C%20et%20al.%20%26%23x201C%3BTargeted%20High-Throughput%20Sequencing%20for%20Hematological%20Malignancies%3A%20A%20GBMHM%20Survey%20of%20Practice%20and%20Cost%20Evaluation%20in%20France.%26%23x201D%3B%20%3Ci%3EHemaSphere%3C%5C%2Fi%3E%207%2C%20no.%209%20%28September%202023%29%3A%20e943.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FHS9.0000000000000943%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1097%5C%2FHS9.0000000000000943%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Targeted%20High-throughput%20Sequencing%20for%20Hematological%20Malignancies%3A%20A%20GBMHM%20Survey%20of%20Practice%20and%20Cost%20Evaluation%20in%20France%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meryl%22%2C%22lastName%22%3A%22Darlington%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Sujobert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Kosmider%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Luque%20Paz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Kaltenbach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Figeac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Hayette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nadia%22%2C%22lastName%22%3A%22Mezaour%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9verine%22%2C%22lastName%22%3A%22Coquerelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Sophie%22%2C%22lastName%22%3A%22Alary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Le%20Bris%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Davi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Preudhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Durand-Zaleski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Macintyre%22%7D%5D%2C%22abstractNote%22%3A%22The%20objective%20of%20this%20study%20was%20to%20assess%20the%20clinical%20impact%20and%20financial%20costs%20of%20next-generation%20sequencing%20%28NGS%29%20in%205%20categories%20of%20pediatric%20and%20adult%20hematological%20cancers.%20NGS%20prescriptions%20were%20prospectively%20collected%20from%2026%20laboratories%2C%20with%20varied%20technical%20and%20reporting%20practice%20%28all%20or%20only%20significant%20targets%29.%20Impact%20was%20defined%20by%20the%20identification%20of%20%281%29%20an%20actionable%20mutation%2C%20%282%29%20a%20mutation%20with%20prognostic%20and%5C%2For%20theranostic%20value%2C%20and%5C%2For%20%283%29%20a%20mutation%20allowing%20nosological%20refinement%2C%20reported%20by%20local%20investigators.%20A%20microcosting%20study%20was%20undertaken%20in%204%20laboratories%2C%20identifying%20the%20types%20and%20volumes%20of%20resources%20required%20for%20each%20procedural%20step.%20Individual%20index%20prescriptions%20for%203961%20patients%20were%20available%20for%20impact%20analysis%20on%20the%20management%20of%20myeloid%20disorders%20%28two%20thirds%29%20and%2C%20mainly%20mature%20B%2C%20lymphoid%20disorders%20%28one%20third%29.%20NGS%20results%20were%20considered%20to%20impact%20the%20management%20for%2073.4%25%20of%20prescriptions%3A%20useful%20for%20evaluation%20of%20prognostic%20risk%20in%2034.9%25%20and%20necessary%20for%20treatment%20adaptation%20%28actionable%29%20in%2019.6%25%2C%20but%20having%20no%20immediate%20individual%20therapeutic%20impact%20in%2018.9%25.%20The%20average%20overall%20cost%20per%20sample%20was%20191%20%5Cu20ac%20for%20the%20restricted%20mature%20lymphoid%20amplicon%20panel.%20Capture%20panel%20costs%20varied%20from%20369%20%5Cu20ac%20to%20513%20%5Cu20ac.%20Unit%20costs%20varied%20from%200.5%20%5Cu20ac%20to%205.7%20%5Cu20ac%20per%20kb%20sequenced%2C%20from%203.6%20%5Cu20ac%20to%2011.3%20%5Cu20ac%20per%20target%20gene%5C%2Fhot-spot%20sequenced%20and%20from%204.3%20%5Cu20ac%20to%2073.8%20%5Cu20ac%20per%20target%20gene%5C%2Fhot-spot%20reported.%20Comparable%20costs%20for%20the%20Amplicon%20panels%20were%205-8%20%5Cu20ac%20per%20kb%20and%2010.5-14.7%20%5Cu20ac%20per%20target%20gene%5C%2Fhot-spot%20sequenced%20and%20reported%2C%20demonstrating%20comparable%20costs%20with%20greater%20informativity%5C%2Fflexibility%20for%20capture%20strategies.%20Sustainable%20funding%20of%20precision%20medicine%20requires%20a%20transparent%20discussion%20of%20its%20impact%20on%20care%20pathways%20and%20its%20financial%20aspects.%22%2C%22date%22%3A%222023-09%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1097%5C%2FHS9.0000000000000943%22%2C%22ISSN%22%3A%222572-9241%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-08-28T15%3A16%3A36Z%22%7D%7D%2C%7B%22key%22%3A%228N9R5FCH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pelletier%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-21%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPelletier%2C%20Jeoffrey%2C%20Marielle%20Balzano%2C%20J%26%23xE9%3Br%26%23xF4%3Bme%20Destin%2C%20Camille%20Montersino%2C%20Marjorie%20C.%20Delahaye%2C%20Tony%20Marchand%2C%20Anne-Laure%20Bailly%2C%20et%20al.%20%26%23x201C%3BNiche-Expressed%20Galectin-1%20Is%20Involved%20in%20Pre-B%20Acute%20Lymphoblastic%20Leukemia%20Relapse%20through%20Pre-B%20Cell%20Receptor%20Activation.%26%23x201D%3B%20%3Ci%3EIScience%3C%5C%2Fi%3E%20iScience%2C%20no.%204%20%28April%2021%2C%202023%29%3A%20106385.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2023.106385%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.isci.2023.106385%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Niche-expressed%20Galectin-1%20is%20involved%20in%20pre-B%20acute%20lymphoblastic%20leukemia%20relapse%20through%20pre-B%20cell%20receptor%20activation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeoffrey%22%2C%22lastName%22%3A%22Pelletier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marielle%22%2C%22lastName%22%3A%22Balzano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J%5Cu00e9r%5Cu00f4me%22%2C%22lastName%22%3A%22Destin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Montersino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjorie%20C.%22%2C%22lastName%22%3A%22Delahaye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tony%22%2C%22lastName%22%3A%22Marchand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Laure%22%2C%22lastName%22%3A%22Bailly%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florence%22%2C%22lastName%22%3A%22Bardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Coppin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Armelle%22%2C%22lastName%22%3A%22Goubard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Remy%22%2C%22lastName%22%3A%22Castellano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marjolein%20J.%20W.%22%2C%22lastName%22%3A%22de%20Bruijn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jasper%22%2C%22lastName%22%3A%22Rip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Collette%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Dubreuil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karin%22%2C%22lastName%22%3A%22Tarte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Broccardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rudi%20W.%22%2C%22lastName%22%3A%22Hendriks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudine%22%2C%22lastName%22%3A%22Schiff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Vey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michel%22%2C%22lastName%22%3A%22Aurrand-Lions%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%20J.%20C.%22%2C%22lastName%22%3A%22Mancini%22%7D%5D%2C%22abstractNote%22%3A%22B-cell%20acute%20lymphoblastic%20leukemia%20%28B-ALL%29%20reflects%20the%20malignant%20counterpart%20of%20developing%20B%20cells%20in%20the%20bone%20marrow%20%28BM%29.%20Despite%20tremendous%20progress%20in%20B-ALL%20treatment%2C%20the%20overall%20survival%20of%20adults%20at%20diagnosis%20and%20patients%20at%20all%20ages%20after%20relapse%20remains%20poor.%20Galectin-1%20%28GAL1%29%20expressed%20by%20BM%20supportive%20niches%20delivers%20proliferation%20signals%20to%20normal%20pre-B%20cells%20through%20interaction%20with%20the%20pre-B%20cell%20receptor%20%28pre-BCR%29.%20Here%2C%20we%20asked%20whether%20GAL1%20gives%20non-cell%20autonomous%20signals%20to%20pre-BCR%2B%20pre-B%20ALL%2C%20in%20addition%20to%20cell-autonomous%20signals%20linked%20to%20genetic%20alterations.%20In%20syngeneic%20and%20patient-derived%20xenograft%20%28PDX%29%20murine%20models%2C%20murine%20and%20human%20pre-B%20ALL%20development%20is%20influenced%20by%20GAL1%20produced%20by%20BM%20niches%20through%20pre-BCR-dependent%20signals%2C%20similarly%20to%20normal%20pre-B%20cells.%20Furthermore%2C%20targeting%20pre-BCR%20signaling%20together%20with%20cell-autonomous%20oncogenic%20pathways%20in%20pre-B%20ALL%20PDX%20improved%20treatment%20response.%20Our%20results%20show%20that%20non-cell%20autonomous%20signals%20transmitted%20by%20BM%20niches%20represent%20promising%20targets%20to%20improve%20B-ALL%20patient%20survival.%22%2C%22date%22%3A%222023-04-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.isci.2023.106385%22%2C%22ISSN%22%3A%222589-0042%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-05-23T09%3A25%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22DARA8KLQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Duployez%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDuployez%2C%20Nicolas%2C%20Lo%26%23xEF%3Bc%20Vasseur%2C%20Rathana%20Kim%2C%20La%26%23xEB%3Btitia%20Largeaud%2C%20Marie%20Passet%2C%20Ana%26%23xEF%3Bs%20L%26%23x2019%3BHaridon%2C%20Pierre%20Lemaire%2C%20et%20al.%20%26%23x201C%3BUBTF%20Tandem%20Duplications%20Define%20a%20Distinct%20Subtype%20of%20Adult%20de%20Novo%20Acute%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2C%20April%2021%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-023-01906-z%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-023-01906-z%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22UBTF%20tandem%20duplications%20define%20a%20distinct%20subtype%20of%20adult%20de%20novo%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Duployez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Vasseur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rathana%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22La%5Cu00ebtitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Passet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%5Cu00efs%22%2C%22lastName%22%3A%22L%27Haridon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Lemaire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laur%5Cu00e8ne%22%2C%22lastName%22%3A%22Fenwarth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Geffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Helevaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karine%22%2C%22lastName%22%3A%22Celli-Lebras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lionel%22%2C%22lastName%22%3A%22Ad%5Cu00e8s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Delphine%22%2C%22lastName%22%3A%22Lebon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Berthon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Marceau-Renaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Meyling%22%2C%22lastName%22%3A%22Cheok%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Lambert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Raffoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Micol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Gardin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Soulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Hunault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Dombret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Itzykson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Clappier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Preudhomme%22%7D%5D%2C%22abstractNote%22%3A%22Tandem%20duplications%20%28TDs%29%20of%20the%20UBTF%20gene%20have%20been%20recently%20described%20as%20a%20recurrent%20alteration%20in%20pediatric%20acute%20myeloid%20leukemia%20%28AML%29.%20Here%2C%20by%20screening%201946%20newly%20diagnosed%20adult%20AML%2C%20we%20found%20that%20UBTF-TDs%20occur%20in%20about%203%25%20of%20patients%20aged%2018-60%20years%2C%20in%20a%20mutually%20exclusive%20pattern%20with%20other%20known%20AML%20subtype-defining%20alterations.%20The%20characteristics%20of%2059%20adults%20with%20UBTF-TD%20AML%20included%20young%20age%20%28median%2037%20years%29%2C%20low%20bone%20marrow%20%28BM%29%20blast%20infiltration%20%28median%2025%25%29%2C%20and%20high%20rates%20of%20WT1%20mutations%20%2861%25%29%2C%20FLT3-ITDs%20%2851%25%29%20and%20trisomy%208%20%2829%25%29.%20BM%20morphology%20frequently%20demonstrates%20dysmyelopoiesis%20albeit%20modulated%20by%20the%20co-occurrence%20of%20FLT3-ITD.%20UBTF-TD%20patients%20have%20lower%20complete%20remission%20%28CR%29%20rates%20%2857%25%20after%201%20course%20and%2076%25%20after%202%20courses%20of%20intensive%20chemotherapy%20%5BICT%5D%29%20than%20UBTF-wild-type%20patients.%20In%20patients%20enrolled%20in%20the%20ALFA-0702%20study%20%28n%5Cu2009%3D%5Cu2009614%20patients%20including%2021%20with%20UBTF-TD%20AML%29%2C%20the%203-year%20disease-free%20survival%20%28DFS%29%20and%20overall%20survival%20of%20UBTF-TD%20patients%20were%2042.9%25%20%2895%25CI%3A%2023.4-78.5%25%29%20and%2057.1%25%20%2895%25CI%3A%2039.5-82.8%25%29%20and%20did%20not%20significantly%20differ%20from%20those%20of%20ELN%202022%20intermediate%5C%2Fadverse%20risk%20patients.%20Finally%2C%20the%20study%20of%20paired%20diagnosis%20and%20relapsed%5C%2Frefractory%20AML%20samples%20suggests%20that%20WT1-mutated%20clones%20are%20frequently%20selected%20under%20ICT.%20This%20study%20supports%20the%20recognition%20of%20UBTF-TD%20AML%20as%20a%20new%20AML%20entity%20in%20adults.%22%2C%22date%22%3A%222023-04-21%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-023-01906-z%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-04-24T08%3A04%3A48Z%22%7D%7D%2C%7B%22key%22%3A%228NDH6ET7%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Largeaud%20et%20al.%22%2C%22parsedDate%22%3A%222023-02-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELargeaud%2C%20Laetitia%2C%20Matthew%20Collin%2C%20Nils%20Monselet%2C%20Francois%20Vergez%2C%20Vincent%20Fregona%2C%20Lise%20Larcher%2C%20Pierre%20Hirsch%2C%20et%20al.%20%26%23x201C%3BSomatic%20Genetic%20Alterations%20Predict%20Haematological%20Progression%20in%20GATA2%20Deficiency.%26%23x201D%3B%20%3Ci%3EHaematologica%3C%5C%2Fi%3E%2C%20February%202%2C%202023.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282250%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3324%5C%2Fhaematol.2022.282250%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Somatic%20genetic%20alterations%20predict%20haematological%20progression%20in%20GATA2%20deficiency%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Collin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nils%22%2C%22lastName%22%3A%22Monselet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Fregona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Larcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Hirsch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Duployez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacinta%22%2C%22lastName%22%3A%22Bustamante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nais%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Nolla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Hamelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christophe%22%2C%22lastName%22%3A%22Habib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mateo%22%2C%22lastName%22%3A%22Meynier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Bellanne-Chantelot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Donadieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flore%20Sicre%22%2C%22lastName%22%3A%22De%20Fontbrune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%22%2C%22lastName%22%3A%22Fieschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alina%22%2C%22lastName%22%3A%22Ferster%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francois%22%2C%22lastName%22%3A%22Delhommeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marlene%22%2C%22lastName%22%3A%22Pasquet%22%7D%5D%2C%22abstractNote%22%3A%22Germline%20GATA2%20mutations%20predispose%20to%20myeloid%20malignancies%20resulting%20from%20the%20progressive%20acquisition%20of%20additional%20somatic%20mutations.%20Here%20we%20describe%20clinical%20and%20biological%20features%20of%2078%20GATA2%20deficient%20patients.%20Hematopoietic%20stem%20and%20progenitor%20cell%20phenotypic%20characterization%20revealed%20an%20exhaustion%20of%20myeloid%20progenitors.%20Somatic%20mutations%20in%20STAG2%2C%20ASXL1%20and%20SETBP1%20genes%20along%20with%20cytogenetic%20abnormalities%20%28monosomy%207%2C%20trisomy%208%2C%20der%281%3B7%29%29%20occurred%20frequently%20in%20patients%20with%20GATA2%20germline%20mutations.%20Patients%20were%20classified%20into%20three%20haematopoietic%20spectra%20based%20on%20bone%20marrow%20cytomorphology.%20No%20somatic%20additional%20mutations%20were%20detected%20in%20patients%20with%20normal%20bone%20marrow%20%28spectrum%200%29%2C%20whereas%20clonal%20haematopoiesis%20mediated%20by%20STAG2%20mutations%20was%20frequent%20in%20those%20with%20a%20hypocellular%20and%5C%2For%20myelodysplastic%20bone%20marrow%20without%20excess%20blasts%20%28spectrum%201%29.%20Finally%2C%20SETBP1%2C%20RAS%20pathway%20and%20RUNX1%20mutations%20were%20predominantly%20associated%20with%20leukemic%20transformation%20stage%20%28spectrum%202%29%2C%20highlighting%20their%20implications%20in%20the%20transformation%20process.%20Specific%20somatic%20alterations%2C%20potentially%20providing%20distinct%20selective%20advantages%20to%20affected%20cells%2C%20are%20therefore%20associated%20with%20the%20clinical%5C%2Fhaematological%20evolution%20of%20GATA2%20syndrome.%20Our%20study%20not%20only%20suggests%20that%20somatic%20genetic%20profiling%20will%20help%20clinicians%20for%20their%20management%20of%20patients%2C%20but%20also%20clarify%20the%20mechanism%20of%20leukemogenesis%20in%20the%20context%20of%20germline%20GATA2%20mutations.%22%2C%22date%22%3A%222023-02-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3324%5C%2Fhaematol.2022.282250%22%2C%22ISSN%22%3A%221592-8721%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-02-03T13%3A03%3A53Z%22%7D%7D%2C%7B%22key%22%3A%22IFVK6NTP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Kim%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EKim%2C%20Rathana%2C%20Hugo%20Bergugnat%2C%20Lise%20Larcher%2C%20Matthieu%20Duchmann%2C%20Marie%20Passet%2C%20Stephanie%20Gachet%2C%20Wendy%20Cuccuini%2C%20et%20al.%20%26%23x201C%3BAdult%20Low%20Hypodiploid%20Acute%20Lymphoblastic%20Leukemia%20Emerges%20from%20Pre-Leukemic%20TP53-Mutant%20Clonal%20Hematopoiesis.%26%23x201D%3B%20%3Ci%3EBlood%20Cancer%20Discovery%3C%5C%2Fi%3E%2C%20January%2011%2C%202023%2C%20BCD-22-0154.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2643-3230.BCD-22-0154%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2643-3230.BCD-22-0154%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Adult%20low%20hypodiploid%20acute%20lymphoblastic%20leukemia%20emerges%20from%20pre-leukemic%20TP53-mutant%20clonal%20hematopoiesis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rathana%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugo%22%2C%22lastName%22%3A%22Bergugnat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lise%22%2C%22lastName%22%3A%22Larcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Duchmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Passet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Gachet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wendy%22%2C%22lastName%22%3A%22Cuccuini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Lafage-Pochitaloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cedric%22%2C%22lastName%22%3A%22Pastoret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Grardel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vahid%22%2C%22lastName%22%3A%22Asnafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beat%20W.%22%2C%22lastName%22%3A%22Schafer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%22%2C%22lastName%22%3A%22Itzykson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lionel%22%2C%22lastName%22%3A%22Ades%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yosr%22%2C%22lastName%22%3A%22Hicheri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Chalandon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Graux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrice%22%2C%22lastName%22%3A%22Chevallier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Hunault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francoise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Veronique%22%2C%22lastName%22%3A%22Lheritier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herve%22%2C%22lastName%22%3A%22Dombret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Soulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rousselot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Boissel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Clappier%22%7D%5D%2C%22abstractNote%22%3A%22Low%20hypodiploidy%20defines%20a%20rare%20subtype%20of%20B-cell%20acute%20lymphoblastic%20leukemia%20%28B-ALL%29%20with%20a%20dismal%20outcome.%20To%20investigate%20the%20genomic%20basis%20of%20low-hypodiploid%20ALL%20%28LH-ALL%29%20in%20adults%2C%20we%20analyzed%20copy-number%20aberrations%2C%20loss-of-heterozygosity%2C%20mutations%20and%20cytogenetics%20data%20in%20a%20prospective%20cohort%20of%20Philadelphia-negative%20B-ALL%20patients%20%28n%3D591%2C%20aged%2018-84y%29%2C%20allowing%20to%20identify%2080%20LH-ALL%20cases%20%2814%25%29.%20Genomic%20analysis%20was%20critical%20for%20evidencing%20low%20hypodiploidy%20in%20many%20cases%20missed%20by%20cytogenetics.%20The%20proportion%20of%20LH-ALL%20dramatically%20increased%20with%20age%2C%20from%203%25%20below%20the%20age%20of%2040%20to%2032%25%20over%2055%20years.%20Somatic%20TP53%20biallelic%20inactivation%20was%20the%20hallmark%20of%20adult%20LH-ALL%2C%20present%20in%20virtually%20all%20cases%20%2898%25%29.%20Strikingly%2C%20we%20detected%20TP53%20mutations%20in%20post-treatment%20remission%20samples%20in%2034%25%20of%20patients.%20Single-cell%20proteogenomics%20of%20diagnosis%20and%20remission%20bone%20marrow%20samples%20evidenced%20a%20preleukemic%2C%20multilineage%2C%20TP53-mutant%20clone%2C%20reminiscent%20of%20age-related%20clonal%20hematopoiesis.%22%2C%22date%22%3A%222023-01-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F2643-3230.BCD-22-0154%22%2C%22ISSN%22%3A%222643-3249%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-01-30T14%3A20%3A17Z%22%7D%7D%2C%7B%22key%22%3A%2279AWGWIC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Canali%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-04%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECanali%2C%20Alban%2C%20In%26%23xE8%3Bs%20Vergnolle%2C%20Sarah%20Bertoli%2C%20Laetitia%20Largeaud%2C%20Marie-Laure%20Nicolau%2C%20Jean-Baptiste%20Rieu%2C%20Suzanne%20Tavitian%2C%20et%20al.%20%26%23x201C%3BPrognostic%20Impact%20of%20Unsupervised%20Early%20Assessment%20of%20Bulk%20and%20Leukemic%20Stem%20Cell%20Measurable%20Residual%20Disease%20in%20Acute%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3EClinical%20Cancer%20Research%3A%20An%20Official%20Journal%20of%20the%20American%20Association%20for%20Cancer%20Research%3C%5C%2Fi%3E%2029%2C%20no.%201%20%28January%204%2C%202023%29%3A%20134%26%23x2013%3B42.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-22-2237%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-22-2237%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Prognostic%20Impact%20of%20Unsupervised%20Early%20Assessment%20of%20Bulk%20and%20Leukemic%20Stem%20Cell%20Measurable%20Residual%20Disease%20in%20Acute%20Myeloid%20Leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alban%22%2C%22lastName%22%3A%22Canali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22In%5Cu00e8s%22%2C%22lastName%22%3A%22Vergnolle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Nicolau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Philippe%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lechevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Christine%22%2C%22lastName%22%3A%22B%5Cu00e9n%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Mansat-De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Acute%20myeloid%20leukemias%20%28AML%29%20are%20clonal%20diseases%20that%20develop%20from%20leukemic%20stem%20cells%20%28LSC%29%20that%20carry%20an%20independent%20prognostic%20impact%20on%20the%20initial%20response%20to%20induction%20chemotherapy%2C%20demonstrating%20the%20clinical%20relevance%20of%20LSC%20abundance%20in%20AML.%20In%202018%2C%20the%20European%20LeukemiaNet%20published%20recommendations%20for%20the%20detection%20of%20measurable%20residual%20disease%20%28Bulk%20MRD%29%20and%20suggested%20the%20exploration%20of%20LSC%20MRD%20and%20the%20use%20of%20multiparametric%20displays.%5CnEXPERIMENTAL%20DESIGN%3A%20We%20evaluated%20the%20performance%20of%20unsupervised%20clustering%20for%20the%20post-induction%20assessment%20of%20bulk%20and%20LSC%20MRD%20in%20155%20patients%20with%20AML%20who%20received%20intensive%20conventional%20chemotherapy%20treatment.%5CnRESULTS%3A%20The%20median%20overall%20survival%20%28OS%29%20for%20Bulk%2B%20MRD%20patients%20was%2016.7%20months%20and%20was%20not%20reached%20for%20negative%20patients%20%28HR%2C%203.82%3B%20P%20%3C%200.0001%29.%20The%20median%20OS%20of%20LSC%2B%20MRD%20patients%20was%2025.0%20months%20and%20not%20reached%20for%20negative%20patients%20%28HR%2C%202.84%3B%20P%20%3D%200.001%29.%20Interestingly%2C%201-year%20%28y%29%20and%203-y%20OS%20were%2060%25%20and%2039%25%20in%20Bulk%2B%2C%2091%25%20and%2052%25%20in%20Bulk-LSC%2B%20and%2092%25%20and%2088%25%20in%20Bulk-LSC-.%5CnCONCLUSIONS%3A%20In%20this%20study%2C%20we%20confirm%20the%20prognostic%20impact%20of%20post-induction%20multiparametric%20flow%20cytometry%20Bulk%20MRD%20in%20patients%20with%20AML.%20Focusing%20on%20LSCs%2C%20we%20identified%20a%20group%20of%20patients%20with%20negative%20Bulk%20MRD%20but%20positive%20LSC%20MRD%20%2825.8%25%20of%20our%20cohort%29%20with%20an%20intermediate%20prognosis%2C%20demonstrating%20the%20interest%20of%20MRD%20analysis%20focusing%20on%20leukemic%20chemoresistant%20subpopulations.%22%2C%22date%22%3A%222023-01-04%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-22-2237%22%2C%22ISSN%22%3A%221557-3265%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222023-01-30T14%3A19%3A21Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Tamburini, Jerome, Sarah Mouche, Clement Larrue, Nicolas Duployez, Audrey Bidet, Auriane Salotti, Pierre Hirsch, et al. “Very Short Insertions in the FLT3 Gene Are of Therapeutic Significance in Acute Myeloid Leukemia.” Blood Advances<\/i> 7, no. 24 (December 26, 2023): 7576–80. https:\/\/doi.org\/10.1182\/bloodadvances.2023011916<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Faguer, Stanislas, Eric Delabesse, Carle Paul, and Marlène Pasquet. “IL-4Rα Inhibition for Severe ‘Eosinophilic Gastroenteritis, Allergy, and Anaphylaxis’ Syndrome Due to a Gain-of-Function Variant in STAT6.” Journal of Clinical Immunology<\/i> 44, no. 1 (December 22, 2023): 29. https:\/\/doi.org\/10.1007\/s10875-023-01639-9<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Darlington, Meryl, Pierre Sujobert, Olivier Kosmider, Damien Luque Paz, Sophie Kaltenbach, Martin Figeac, Sandrine Hayette, et al. “Targeted High-Throughput Sequencing for Hematological Malignancies: A GBMHM Survey of Practice and Cost Evaluation in France.” HemaSphere<\/i> 7, no. 9 (September 2023): e943. https:\/\/doi.org\/10.1097\/HS9.0000000000000943<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pelletier, Jeoffrey, Marielle Balzano, Jérôme Destin, Camille Montersino, Marjorie C. Delahaye, Tony Marchand, Anne-Laure Bailly, et al. “Niche-Expressed Galectin-1 Is Involved in Pre-B Acute Lymphoblastic Leukemia Relapse through Pre-B Cell Receptor Activation.” IScience<\/i> iScience, no. 4 (April 21, 2023): 106385. https:\/\/doi.org\/10.1016\/j.isci.2023.106385<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Duployez, Nicolas, Loïc Vasseur, Rathana Kim, Laëtitia Largeaud, Marie Passet, Anaïs L’Haridon, Pierre Lemaire, et al. “UBTF Tandem Duplications Define a Distinct Subtype of Adult de Novo Acute Myeloid Leukemia.” Leukemia<\/i>, April 21, 2023. https:\/\/doi.org\/10.1038\/s41375-023-01906-z<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Largeaud, Laetitia, Matthew Collin, Nils Monselet, Francois Vergez, Vincent Fregona, Lise Larcher, Pierre Hirsch, et al. “Somatic Genetic Alterations Predict Haematological Progression in GATA2 Deficiency.” Haematologica<\/i>, February 2, 2023. https:\/\/doi.org\/10.3324\/haematol.2022.282250<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Kim, Rathana, Hugo Bergugnat, Lise Larcher, Matthieu Duchmann, Marie Passet, Stephanie Gachet, Wendy Cuccuini, et al. “Adult Low Hypodiploid Acute Lymphoblastic Leukemia Emerges from Pre-Leukemic TP53-Mutant Clonal Hematopoiesis.” Blood Cancer Discovery<\/i>, January 11, 2023, BCD-22-0154. https:\/\/doi.org\/10.1158\/2643-3230.BCD-22-0154<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Canali, Alban, Inès Vergnolle, Sarah Bertoli, Laetitia Largeaud, Marie-Laure Nicolau, Jean-Baptiste Rieu, Suzanne Tavitian, et al. “Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research<\/i> 29, no. 1 (January 4, 2023): 134–42. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2237<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2022″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.19.0″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t9RREECEZ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2022<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 40076<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-b6e80abeb7c977623b818c22d8bc62c3%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22IJ8TIQSY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Othman%20et%20al.%22%2C%22parsedDate%22%3A%222022-12-12%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EOthman%2C%20Jad%2C%20Manja%20Meggendorfer%2C%20Enrico%20Tiacci%2C%20Christian%20Thiede%2C%20Richard%20F.%20Schlenk%2C%20Richard%20Dillon%2C%20Sebastian%20Stasik%2C%20et%20al.%20%26%23x201C%3BOverlapping%20Features%20of%20Therapy-Related%20and%20de%20NovoNPM1-Mutated%20AML.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%2C%20December%2012%2C%202022%2C%20blood.2022018108.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022018108%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2022018108%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Overlapping%20features%20of%20therapy-related%20and%20de%20novoNPM1-mutated%20AML%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jad%22%2C%22lastName%22%3A%22Othman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manja%22%2C%22lastName%22%3A%22Meggendorfer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Enrico%22%2C%22lastName%22%3A%22Tiacci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Thiede%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%20F.%22%2C%22lastName%22%3A%22Schlenk%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Dillon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastian%22%2C%22lastName%22%3A%22Stasik%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandra%22%2C%22lastName%22%3A%22Venanzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amanda%20Frances%22%2C%22lastName%22%3A%22Gilkes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ian%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Teresa%22%2C%22lastName%22%3A%22Voso%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alessandro%22%2C%22lastName%22%3A%22Rambaldi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenzo%22%2C%22lastName%22%3A%22Brunetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincenzo%20Maria%22%2C%22lastName%22%3A%22Perriello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vibeke%22%2C%22lastName%22%3A%22Andresen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bjorn%20T.%22%2C%22lastName%22%3A%22Gjertsen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Paola%22%2C%22lastName%22%3A%22Martelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Serve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%22%2C%22lastName%22%3A%22M%5Cu00fcller-Tidow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20D.%22%2C%22lastName%22%3A%22Baldus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Torsten%22%2C%22lastName%22%3A%22Haferlach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nigel%20H.%22%2C%22lastName%22%3A%22Russell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brunangelo%22%2C%22lastName%22%3A%22Falini%22%7D%5D%2C%22abstractNote%22%3A%22NPM1-mutated%20AML%20represents%20a%20WHO%20leukemia%20entity%20with%20unique%20pathological%20and%20clinical%20features.%20Little%20is%20known%20about%20the%20characteristics%20of%20%5C%22therapy-related%5C%22%20NPM1-mutated%20AML.%20We%20compared%20the%20genetics%2C%20transcriptional%20profile%20and%20clinical%20outcome%20of%20therapy-related%20NPM1-mutated%20AML%20%28t-NPM1%20AML%29%2C%20de-novo%20NPM1-mutated%20AML%20%28dn-NPM1%20AML%29%20and%20therapy-related%20AML%20with%20wild-type%20NPM1%20%28t-AML%29.%20A%20normal%20karyotype%20was%20more%20frequent%20in%20t-NPM1%20AML%20%28n%3D78%5C%2F96%20cases%2C%2088%25%29%20and%20dn-NPM1%20%28n%3D1986%5C%2F2394%2C88%25%29%20than%20in%20t-AML%20%28n%3D103%5C%2F390%2C28%25%3B%20p%20%3C0.001%29.%20DNMT3A%20and%20TET2%20were%20mutated%20in%2043%25%20and%2040%25%20of%20t-NPM1%20AML%20%28n%3D107%29%2C%20similar%20to%20dn-NPM1%20%28n%3D88%2C%2048%25%20and%2030%25%3B%20p-values%20%3E0.1%29%2C%20but%20more%20frequently%20than%20t-AML%20%28n%3D162%3B%2014%25%20and%2010%25%3B%20p-values%20%3C0.001%29.%20TP53%20and%20PPM1D%2C%20typically%20mutated%20in%20t-AML%2C%20were%20consistently%20wild-type%20in%20t-NPM1%20AML%20%2897%25%20and%2096%25%29.%20t-NPM1%20and%20dn-NPM1%20AML%20were%20transcriptionally%20similar%2C%20displaying%20upregulation%20of%20HOX%20genes%20and%20down-regulation%20of%20CD133%20and%20CD34.%20With%20a%20median%20follow-up%20of%2062%20months%2C%203-year%20overall%20survival%20%28OS%29%20for%20t-NPM1%20AML%20%28n%3D96%29%2C%20dn-NPM1%20AML%20%28n%3D2394%29%20and%20t-AML%20%28n%3D390%29%20was%2054%25%2C%2060%25%20and%2031%25.%20In%20multivariable%20analysis%20OS%20was%20similar%20for%20the%20two%20NPM1-mutated%20groups%20%28HR%200.9%2C%2095%25CI%200.65-1.25%2C%20p%3D0.45%29%20but%20better%20in%20t-NPM1%20AML%20than%20t-AML%20%28HR%201.86%2C%2095%25CI%201.30-2.68%2C%20p%3C0.001%29.%20Relapse-free%20survival%20did%20not%20differ%20between%20t-NPM1%20and%20dn-NPM1%20AML%20%28HR%201.02%2C%2095%25CI%200.72-1.467%2C%20p%3D0.90%29%20but%20was%20significantly%20higher%20in%20t-NPM1%20AML%20than%20t-AML%20%28HR%201.77%2C%2095%25CI%201.19-2.64%2C%20p%3D0.0045%29.t-NPM1%20and%20dn-NPM1%20AML%20have%20similar%20clinical%2C%20genomic%20and%20transcriptomic%20features%2C%20suggesting%20that%20they%20should%20be%20classified%20as%20a%20single%20disease%20entity.%22%2C%22date%22%3A%222022-12-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2022018108%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-12-14T10%3A39%3A57Z%22%7D%7D%2C%7B%22key%22%3A%22DDBAZ2NR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lafage-Pochitaloff%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-25%22%2C%22numChildren%22%3A3%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELafage-Pochitaloff%2C%20Marina%2C%20Bastien%20Gerby%2C%20V%26%23xE9%3Bronique%20Baccini%2C%20Laetitia%20Largeaud%2C%20Vincent%20Fregona%2C%20Na%26%23xEF%3Bs%20Prade%2C%20Pierre-Yves%20Juvin%2C%20et%20al.%20%26%23x201C%3BThe%20CADM1%20Tumor%20Suppressor%20Gene%20Is%20a%20Major%20Candidate%20Gene%20in%20MDS%20with%20Deletion%20of%20the%20Long%20Arm%20of%20Chromosome%2011.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%206%2C%20no.%202%20%28January%2025%2C%202022%29%3A%20386%26%23x2013%3B98.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021005311%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021005311%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20CADM1%20tumor%20suppressor%20gene%20is%20a%20major%20candidate%20gene%20in%20MDS%20with%20deletion%20of%20the%20long%20arm%20of%20chromosome%2011%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Lafage-Pochitaloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Gerby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Baccini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Fregona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Juvin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%22%2C%22lastName%22%3A%22Jamrog%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22H%5Cu00e9brard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Mansat-De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Oliver%20M.%22%2C%22lastName%22%3A%22Dovey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kosuke%22%2C%22lastName%22%3A%22Yusa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20S.%22%2C%22lastName%22%3A%22Vassiliou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joop%20H.%22%2C%22lastName%22%3A%22Jansen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tobias%22%2C%22lastName%22%3A%22Tekath%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Rombaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Genevi%5Cu00e8ve%22%2C%22lastName%22%3A%22Ameye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Barin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Boudjarane%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Agn%5Cu00e8s%22%2C%22lastName%22%3A%22Collonge-Rame%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carine%22%2C%22lastName%22%3A%22Gervais%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Ittel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucienne%22%2C%22lastName%22%3A%22Michaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Nadal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%20A.%22%2C%22lastName%22%3A%22Poirel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Radford-Weiss%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Ribourtout%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Richebourg%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Struski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Terr%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Tigaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Penther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Eclache%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michaela%22%2C%22lastName%22%3A%22Fontenay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Broccardo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%5D%2C%22abstractNote%22%3A%22Myelodysplastic%20syndromes%20%28MDS%29%20represent%20a%20heterogeneous%20group%20of%20clonal%20hematopoietic%20stem%20cell%20disorders%20characterized%20by%20ineffective%20hematopoiesis%20leading%20to%20peripheral%20cytopenias%20and%20in%20a%20substantial%20proportion%20of%20cases%20to%20acute%20myeloid%20leukemia.%20The%20deletion%20of%20the%20long%20arm%20of%20chromosome%2011%2C%20del%2811q%29%2C%20is%20a%20rare%20but%20recurrent%20clonal%20event%20in%20MDS.%20Here%2C%20we%20detail%20the%20largest%20series%20of%20113%20cases%20of%20MDS%20and%20myelodysplastic%20syndromes%5C%2Fmyeloproliferative%20neoplasms%20%28MDS%5C%2FMPN%29%20harboring%20a%20del%2811q%29%20analyzed%20at%20clinical%2C%20cytological%2C%20cytogenetic%2C%20and%20molecular%20levels.%20Female%20predominance%2C%20a%20survival%20prognosis%20similar%20to%20other%20MDS%2C%20a%20low%20monocyte%20count%2C%20and%20dysmegakaryopoiesis%20were%20the%20specific%20clinical%20and%20cytological%20features%20of%20del%2811q%29%20MDS.%20In%20most%20cases%2C%20del%2811q%29%20was%20isolated%2C%20primary%20and%20interstitial%20encompassing%20the%2011q22-23%20region%20containing%20ATM%2C%20KMT2A%2C%20and%20CBL%20genes.%20The%20common%20deleted%20region%20at%2011q23.2%20is%20centered%20on%20an%20intergenic%20region%20between%20CADM1%20%28also%20known%20as%20Tumor%20Suppressor%20in%20Lung%20Cancer%201%29%20and%20NXPE2.%20CADM1%20was%20expressed%20in%20all%20myeloid%20cells%20analyzed%20in%20contrast%20to%20NXPE2.%20At%20the%20functional%20level%2C%20the%20deletion%20of%20Cadm1%20in%20murine%20Lineage-Sca1%2BKit%2B%20cells%20modifies%20the%20lymphoid-to-myeloid%20ratio%20in%20bone%20marrow%2C%20although%20not%20altering%20their%20multilineage%20hematopoietic%20reconstitution%20potential%20after%20syngenic%20transplantation.%20Together%20with%20the%20frequent%20simultaneous%20deletions%20of%20KMT2A%2C%20ATM%2C%20and%20CBL%20and%20mutations%20of%20ASXL1%2C%20SF3B1%2C%20and%20CBL%2C%20we%20show%20that%20CADM1%20may%20be%20important%20in%20the%20physiopathology%20of%20the%20del%2811q%29%20MDS%2C%20extending%20its%20role%20as%20tumor-suppressor%20gene%20from%20solid%20tumors%20to%20hematopoietic%20malignancies.%22%2C%22date%22%3A%222022-01-25%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2021005311%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A10%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22RGZWCYK5%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Largeaud%20et%20al.%22%2C%22parsedDate%22%3A%222022-01-05%22%2C%22numChildren%22%3A4%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELargeaud%2C%20Laetitia%2C%20Sarah%20Bertoli%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Suzanne%20Tavitian%2C%20Muriel%20Picard%2C%20St%26%23xE9%3Bphanie%20Dufrechou%2C%20Na%26%23xEF%3Bs%20Prade%2C%20et%20al.%20%26%23x201C%3BGenomic%20Landscape%20of%20Hyperleukocytic%20Acute%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3EBlood%20Cancer%20Journal%3C%5C%2Fi%3E%2012%2C%20no.%201%20%28January%205%2C%202022%29%3A%204.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41408-021-00601-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41408-021-00601-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Genomic%20landscape%20of%20hyperleukocytic%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Picard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Ruiz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222022-01-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41408-021-00601-5%22%2C%22ISSN%22%3A%222044-5385%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%223U3NWA3K%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A12%3A05Z%22%7D%7D%2C%7B%22key%22%3A%229QNV63YR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Veiga%20et%20al.%22%2C%22parsedDate%22%3A%222022%22%2C%22numChildren%22%3A11%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVeiga%2C%20Diogo%20F.%20T.%2C%20Mathieu%20Tremblay%2C%20Bastien%20Gerby%2C%20Sabine%20Herblot%2C%20Andr%26%23xE9%3B%20Haman%2C%20Patrick%20Gendron%2C%20S%26%23xE9%3Bbastien%20Lemieux%2C%20et%20al.%20%26%23x201C%3BMonoallelic%20Heb%5C%2FTcf12%20Deletion%20Reduces%20the%20Requirement%20for%20NOTCH1%20Hyperactivation%20in%20T-Cell%20Acute%20Lymphoblastic%20Leukemia.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Immunology%3C%5C%2Fi%3E%2013%20%282022%29%3A%20867443.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.867443%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffimmu.2022.867443%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Monoallelic%20Heb%5C%2FTcf12%20Deletion%20Reduces%20the%20Requirement%20for%20NOTCH1%20Hyperactivation%20in%20T-Cell%20Acute%20Lymphoblastic%20Leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diogo%20F.%20T.%22%2C%22lastName%22%3A%22Veiga%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathieu%22%2C%22lastName%22%3A%22Tremblay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Gerby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Herblot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Haman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Patrick%22%2C%22lastName%22%3A%22Gendron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Lemieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%20Carlos%22%2C%22lastName%22%3A%22Z%5Cu00fa%5Cu00f1iga-Pfl%5Cu00fccker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9e%22%2C%22lastName%22%3A%22H%5Cu00e9bert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20Paul%22%2C%22lastName%22%3A%22Cohen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trang%22%2C%22lastName%22%3A%22Hoang%22%7D%5D%2C%22abstractNote%22%3A%22Early%20T-cell%20development%20is%20precisely%20controlled%20by%20E%20proteins%2C%20that%20indistinguishably%20include%20HEB%5C%2FTCF12%20and%20E2A%5C%2FTCF3%20transcription%20factors%2C%20together%20with%20NOTCH1%20and%20pre-T%20cell%20receptor%20%28TCR%29%20signalling.%20Importantly%2C%20perturbations%20of%20early%20T-cell%20regulatory%20networks%20are%20implicated%20in%20leukemogenesis.%20NOTCH1%20gain%20of%20function%20mutations%20invariably%20lead%20to%20T-cell%20acute%20lymphoblastic%20leukemia%20%28T-ALL%29%2C%20whereas%20inhibition%20of%20E%20proteins%20accelerates%20leukemogenesis.%20Thus%2C%20NOTCH1%2C%20pre-TCR%2C%20E2A%20and%20HEB%20functions%20are%20intertwined%2C%20but%20how%20these%20pathways%20contribute%20individually%20or%20synergistically%20to%20leukemogenesis%20remain%20to%20be%20documented.%20To%20directly%20address%20these%20questions%2C%20we%20leveraged%20Cd3e-deficient%20mice%20in%20which%20pre-TCR%20signaling%20and%20progression%20through%20%5Cu03b2-selection%20is%20abrogated%20to%20dissect%20and%20decouple%20the%20roles%20of%20pre-TCR%2C%20NOTCH1%2C%20E2A%20and%20HEB%20in%20SCL%5C%2FTAL1-induced%20T-ALL%2C%20via%20the%20use%20of%20Notch1%20gain%20of%20function%20transgenic%20%28Notch1IC%20tg%29%20and%20Tcf12%20%2B%5C%2F-%20or%20Tcf3%20%2B%5C%2F-%20heterozygote%20mice.%20As%20a%20result%2C%20we%20now%20provide%20evidence%20that%20both%20HEB%20and%20E2A%20restrain%20cell%20proliferation%20at%20the%20%5Cu03b2-selection%20checkpoint%20while%20the%20clonal%20expansion%20of%20SCL-LMO1-induced%20pre-leukemic%20stem%20cells%20in%20T-ALL%20is%20uniquely%20dependent%20on%20Tcf12%20gene%20dosage.%20At%20the%20molecular%20level%2C%20HEB%20protein%20levels%20are%20decreased%20via%20proteasomal%20degradation%20at%20the%20leukemic%20stage%2C%20pointing%20to%20a%20reversible%20loss%20of%20function%20mechanism.%20Moreover%2C%20in%20SCL-LMO1-induced%20T-ALL%2C%20loss%20of%20one%20Tcf12%20allele%20is%20sufficient%20to%20bypass%20pre-TCR%20signaling%20which%20is%20required%20for%20Notch1%20gain%20of%20function%20mutations%20and%20for%20progression%20to%20T-ALL.%20In%20contrast%2C%20Tcf12%20monoallelic%20deletion%20does%20not%20accelerate%20Notch1IC-induced%20T-ALL%2C%20indicating%20that%20Tcf12%20and%20Notch1%20operate%20in%20the%20same%20pathway.%20Finally%2C%20we%20identify%20a%20tumor%20suppressor%20gene%20set%20downstream%20of%20HEB%2C%20exhibiting%20significantly%20lower%20expression%20levels%20in%20pediatric%20T-ALL%20compared%20to%20B-ALL%20and%20brain%20cancer%20samples%2C%20the%20three%20most%20frequent%20pediatric%20cancers.%20In%20summary%2C%20our%20results%20indicate%20a%20tumor%20suppressor%20function%20of%20HEB%5C%2FTCF12%20in%20T-ALL%20to%20mitigate%20cell%20proliferation%20controlled%20by%20NOTCH1%20in%20pre-leukemic%20stem%20cells%20and%20prevent%20NOTCH1-driven%20progression%20to%20T-ALL.%22%2C%22date%22%3A%222022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffimmu.2022.867443%22%2C%22ISSN%22%3A%221664-3224%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-10-04T08%3A11%3A35Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Othman, Jad, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard F. Schlenk, Richard Dillon, Sebastian Stasik, et al. “Overlapping Features of Therapy-Related and de NovoNPM1-Mutated AML.” Blood<\/i>, December 12, 2022, blood.2022018108. https:\/\/doi.org\/10.1182\/blood.2022018108<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lafage-Pochitaloff, Marina, Bastien Gerby, Véronique Baccini, Laetitia Largeaud, Vincent Fregona, Naïs Prade, Pierre-Yves Juvin, et al. “The CADM1 Tumor Suppressor Gene Is a Major Candidate Gene in MDS with Deletion of the Long Arm of Chromosome 11.” Blood Advances<\/i> 6, no. 2 (January 25, 2022): 386–98. https:\/\/doi.org\/10.1182\/bloodadvances.2021005311<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Largeaud, Laetitia, Sarah Bertoli, Emilie Bérard, Suzanne Tavitian, Muriel Picard, Stéphanie Dufrechou, Naïs Prade, et al. “Genomic Landscape of Hyperleukocytic Acute Myeloid Leukemia.” Blood Cancer Journal<\/i> 12, no. 1 (January 5, 2022): 4. https:\/\/doi.org\/10.1038\/s41408-021-00601-5<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Veiga, Diogo F. T., Mathieu Tremblay, Bastien Gerby, Sabine Herblot, André Haman, Patrick Gendron, Sébastien Lemieux, et al. “Monoallelic Heb\/Tcf12 Deletion Reduces the Requirement for NOTCH1 Hyperactivation in T-Cell Acute Lymphoblastic Leukemia.” Frontiers in Immunology<\/i> 13 (2022): 867443. https:\/\/doi.org\/10.3389\/fimmu.2022.867443<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2021″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#ffffff” title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t9RREECEZ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2021<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 40076<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-4c358119219d3d3eaeb3618d8bb710be%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%229BEXSSSN%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22R%5Cu00e9cher%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ER%26%23xE9%3Bcher%2C%20Christian%2C%20Christoph%20R%26%23xF6%3Bllig%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Sarah%20Bertoli%2C%20Pierre-Yves%20Dumas%2C%20Suzanne%20Tavitian%2C%20Michael%20Kramer%2C%20et%20al.%20%26%23x201C%3BLong-Term%20Survival%20after%20Intensive%20Chemotherapy%20or%20Hypomethylating%20Agents%20in%20AML%20Patients%20Aged%2070%20Years%20and%20Older%3A%20A%20Large%20Patient%20Data%20Set%20Study%20from%20European%20Registries.%26%23x201D%3B%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2C%20November%2013%2C%202021.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-021-01425-9%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-021-01425-9%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20survival%20after%20intensive%20chemotherapy%20or%20hypomethylating%20agents%20in%20AML%20patients%20aged%2070%20years%20and%20older%3A%20a%20large%20patient%20data%20set%20study%20from%20European%20registries%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christoph%22%2C%22lastName%22%3A%22R%5Cu00f6llig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%22%2C%22lastName%22%3A%22Kramer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hubert%22%2C%22lastName%22%3A%22Serve%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Bornh%5Cu00e4user%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Uwe%22%2C%22lastName%22%3A%22Platzbecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carsten%22%2C%22lastName%22%3A%22M%5Cu00fcller-Tidow%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudia%20D.%22%2C%22lastName%22%3A%22Baldus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-Cuadr%5Cu00f3n%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Josefina%22%2C%22lastName%22%3A%22Serrano%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pilar%22%2C%22lastName%22%3A%22Mart%5Cu00ednez-S%5Cu00e1nchez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%20Rodr%5Cu00edguez%22%2C%22lastName%22%3A%22Arbol%5Cu00ed%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Gil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Bergua%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Teresa%22%2C%22lastName%22%3A%22Bernal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adolfo%22%2C%22lastName%22%3A%22de%20la%20Fuente%20Burguera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pau%22%2C%22lastName%22%3A%22Montesinos%22%7D%5D%2C%22abstractNote%22%3A%22The%20outcome%20of%20acute%20myeloid%20leukemia%20patients%20aged%2070%20years%20or%20older%20is%20poor.%20Defining%20the%20best%20treatment%20option%20remains%20controversial%20especially%20when%20choosing%20between%20intensive%20chemotherapy%20and%20hypomethylating%20agents.%20We%20set%20up%20a%20multicentric%20European%20database%20collecting%20data%20of%203%20700%20newly%20diagnosed%20acute%20myeloid%20leukemia%20patients%20%5Cu226570%20years.%20The%20primary%20objective%20was%20to%20compare%20overall%20survival%20in%20patients%20selected%20for%20intensive%20chemotherapy%20%28n%5Cu2009%3D%5Cu20091199%29%20or%20hypomethylating%20agents%20%28n%5Cu2009%3D%5Cu20091073%29.%20With%20a%20median%20follow-up%20of%2049.5%20months%2C%20the%20median%20overall%20survival%20was%2010.9%20%2895%25%20CI%3A%209.7-11.6%29%20and%209.2%20months%20%2895%25%20CI%3A%208.3-10.2%29%20with%20chemotherapy%20and%20hypomethylating%20agents%2C%20respectively.%20Complete%20remission%20or%20complete%20remission%20with%20incomplete%20hematologic%20recovery%20was%2056.1%25%20and%2019.7%25%20with%20chemotherapy%20and%20hypomethylating%20agents%2C%20respectively%20%28P%5Cu2009%3C%5Cu20090.0001%29.%20Treatment%20effect%20on%20overall%20survival%20was%20time-dependent.%20The%20Royston%20and%20Parmar%20model%20showed%20that%20patients%20treated%20with%20hypomethylating%20agents%20had%20a%20significantly%20lower%20risk%20of%20death%20before%201.5%20months%20of%20follow-up%3B%20no%20significant%20difference%20between%201.5%20and%204.0%20months%2C%20whereas%20patients%20treated%20with%20intensive%20chemotherapy%20had%20a%20significantly%20better%20overall%20survival%20from%20four%20months%20after%20start%20of%20therapy.%20This%20study%20shows%20that%20intensive%20chemotherapy%20remains%20a%20valuable%20option%20associated%20with%20a%20better%20long-term%20survival%20in%20older%20AML%20patients.%22%2C%22date%22%3A%222021-11-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-021-01425-9%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-01-14T16%3A00%3A16Z%22%7D%7D%2C%7B%22key%22%3A%22Y9FNNFQG%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Galtier%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-13%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGaltier%2C%20Jean%2C%20Camille%20Alric%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Thibaut%20Leguay%2C%20Suzanne%20Tavitian%2C%20Audrey%20Bidet%2C%20Eric%20Delabesse%2C%20et%20al.%20%26%23x201C%3BIntermediate-Dose%20Cytarabine%20or%20Standard-Dose%20Cytarabine%20plus%20Single-Dose%20Anthracycline%20as%20Post-Remission%20Therapy%20in%20Older%20Patients%20with%20Acute%20Myeloid%20Leukemia%3A%20Impact%20on%20Health%20Care%20Resource%20Consumption%20and%20Outcomes.%26%23x201D%3B%20%3Ci%3EBlood%20Cancer%20Journal%3C%5C%2Fi%3E%2011%2C%20no.%2011%20%28November%2013%2C%202021%29%3A%20180.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41408-021-00551-y%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41408-021-00551-y%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Intermediate-dose%20cytarabine%20or%20standard-dose%20cytarabine%20plus%20single-dose%20anthracycline%20as%20post-remission%20therapy%20in%20older%20patients%20with%20acute%20myeloid%20leukemia%3A%20impact%20on%20health%20care%20resource%20consumption%20and%20outcomes%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Galtier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Alric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lechevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Charlotte%22%2C%22lastName%22%3A%22de%20Grande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-11-13%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41408-021-00551-y%22%2C%22ISSN%22%3A%222044-5385%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A51%3A38Z%22%7D%7D%2C%7B%22key%22%3A%227JJDEEJ4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fregona%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFregona%2C%20Vincent%2C%20Manon%20Bayet%2C%20and%20Bastien%20Gerby.%20%26%23x201C%3BOncogene-Induced%20Reprogramming%20in%20Acute%20Lymphoblastic%20Leukemia%3A%20Towards%20Targeted%20Therapy%20of%20Leukemia-Initiating%20Cells.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2013%2C%20no.%2021%20%28November%202%2C%202021%29%3A%205511.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13215511%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers13215511%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Oncogene-Induced%20Reprogramming%20in%20Acute%20Lymphoblastic%20Leukemia%3A%20Towards%20Targeted%20Therapy%20of%20Leukemia-Initiating%20Cells%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Fregona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Bayet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Gerby%22%7D%5D%2C%22abstractNote%22%3A%22Our%20understanding%20of%20the%20hierarchical%20structure%20of%20acute%20leukemia%20has%20yet%20to%20be%20fully%20translated%20into%20therapeutic%20approaches.%20Indeed%2C%20chemotherapy%20still%20has%20to%20take%20into%20account%20the%20possibility%20that%20leukemia-initiating%20cells%20may%20have%20a%20distinct%20chemosensitivity%20profile%20compared%20to%20the%20bulk%20of%20the%20tumor%2C%20and%20therefore%20are%20spared%20by%20the%20current%20treatment%2C%20causing%20the%20relapse%20of%20the%20disease.%20Therefore%2C%20the%20identification%20of%20the%20cell-of-origin%20of%20leukemia%20remains%20a%20longstanding%20question%20and%20an%20exciting%20challenge%20in%20cancer%20research%20of%20the%20last%20few%20decades.%20With%20a%20particular%20focus%20on%20acute%20lymphoblastic%20leukemia%2C%20we%20present%20in%20this%20review%20the%20previous%20and%20current%20concepts%20exploring%20the%20phenotypic%2C%20genetic%20and%20functional%20heterogeneity%20in%20patients.%20We%20also%20discuss%20the%20benefits%20of%20using%20engineered%20mouse%20models%20to%20explore%20the%20early%20steps%20of%20leukemia%20development%20and%20to%20identify%20the%20biological%20mechanisms%20driving%20the%20emergence%20of%20leukemia-initiating%20cells.%20Finally%2C%20we%20describe%20the%20major%20prospects%20for%20the%20discovery%20of%20new%20therapeutic%20strategies%20that%20specifically%20target%20their%20aberrant%20stem%20cell-like%20functions.%22%2C%22date%22%3A%222021-11-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers13215511%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A51%3A17Z%22%7D%7D%2C%7B%22key%22%3A%22N96ZI2K4%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Pavone%20et%20al.%22%2C%22parsedDate%22%3A%222021-11-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPavone%2C%20Rossana%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Pacquement%2C%20Marl%26%23xE8%3Bne%20Pasquet%2C%20H%26%23xE9%3Bl%26%23xE8%3Bne%20Sudour-Bonnange%2C%20F%26%23xE9%3Bd%26%23xE9%3Bric%20Hameury%2C%20Sabine%20Sarnacki%2C%20Pascal%20Chastagner%2C%20et%20al.%20%26%23x201C%3BChildhood%20Ovarian%20Nonseminomatous%20Germ%20Cell%20Tumors%3A%20A%20Highly%20Curable%20Disease%20with%20Few%20Long-Term%20Treatment-Related%20Toxicities-Results%20of%20the%20French%20TGM95%20Study.%26%23x201D%3B%20%3Ci%3EInternational%20Journal%20of%20Cancer%3C%5C%2Fi%3E%20149%2C%20no.%209%20%28November%201%2C%202021%29%3A%201705%26%23x2013%3B12.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.33710%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fijc.33710%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Childhood%20ovarian%20nonseminomatous%20germ%20cell%20tumors%3A%20A%20highly%20curable%20disease%20with%20few%20long-term%20treatment-related%20toxicities-Results%20of%20the%20French%20TGM95%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rossana%22%2C%22lastName%22%3A%22Pavone%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Pacquement%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marl%5Cu00e8ne%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Sudour-Bonnange%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9d%5Cu00e9ric%22%2C%22lastName%22%3A%22Hameury%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sabine%22%2C%22lastName%22%3A%22Sarnacki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Chastagner%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Faure-Conter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marilyne%22%2C%22lastName%22%3A%22Poir%5Cu00e9e%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Taque%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Patte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brice%22%2C%22lastName%22%3A%22Fresneau%22%7D%5D%2C%22abstractNote%22%3A%22We%20report%20survival%20and%20late%20effects%20analysis%20of%20TGM95%20study%20for%20childhood%20%28%5Cu226418%5Cu2009years%29%20ovarian%20nonseminomatous%20germ%20cell%20tumors%20%28NS-GCT%29.%20Patients%20with%20localized%20tumors%20%28FIGO-stage%20IA%29%20had%20no%20adjuvant%20treatment%20%28low-risk%2C%20LR%29.%20Patients%20with%20advanced-stage%20received%203-5%20VBP%20%28vinblastin-bleomycin-cisplatin%29%20in%20intermediate-risk%20group%20%28IR%3A%20FIGO-stage%20IC-II-III%20and%20AFP%5Cu2009%3C%5Cu200915%5Cu2009000%5Cu2009ng%5C%2FmL%29%20or%204-6%20VIP%20%28etoposide-ifosfamide-cisplatin%29%20in%20high-risk%20group%20%28HiR%3A%20metastatic%20or%20AFP%5Cu2009%5Cu2265%5Cu200915%5Cu2009000%5Cu2009ng%5C%2FmL%29.%20Seventy-seven%20patients%20were%20included%20%28median%20age%5Cu00a0%3D%5Cu00a012%5Cu2009years%29%3A%2014%20LR%20%2813%20FIGO-stage%20IA%2C%201%20retrospectively%20IC%29%2C%2026%20IR%20%2812%20IC%2C%2012%20II-III%2C%202%20not-available%29%20and%2037%20HiR%20%282%20IA%20with%20AFP%5Cu2009%5Cu2265%5Cu200915%5Cu2009000%5Cu2009ng%5C%2FmL%2C%2027%20II-III%2C%208%20IV%29.%20After%20a%20median%20follow-up%20of%2013.4%5Cu2009years%2C%2012%20events%20%28eight%20relapses%29%20and%20six%20deaths%20%28two%20GCT-related%2C%20two%20due%20to%20acute%20myeloid%20leukemia%20and%20two%20noncancer%20related%29%20occurred.%20All%20relapses%20%286%20LR%2C%201%20IR%29%20occurred%20within%202%5Cu2009years.%20Four%20contralateral%20mature%20teratomas%20were%20observed%20within%208%5Cu2009years.%20Five-year%20EFS%20and%20OS%20were%2088.2%25%20%2895%25CI%5Cu00a0%3D%5Cu00a079-94%25%29%20and%2094.6%25%20%2895%25CI%5Cu00a0%3D%5Cu00a087-98%25%29.%20Seven%20patients%20%289%25%29%20had%20bilateral%20gonadectomy.%20Among%2051%20survivors%20at%202%5Cu2009years%20aged%20%3E15%5Cu2009years%20%28median%5Cu00a0%3D%5Cu00a026%5Cu2009years%29%20with%20remaining%20ovarian%20tissue%2C%20all%20had%20developed%20spontaneous%20puberty%20and%2021%20%2841%25%29%20had%20at%20least%20one%20pregnancy%20%28including%20two%20with%20infertility%20treatment%29.%20Among%2069%20patients%20treated%20with%20platinum-based%20chemotherapy%2C%20chronic-kidney-disease%20was%20diagnosed%20in%20four%20patients%20%28three%20after%20VIP%29%20and%20significant%20ototoxicity%20occurred%20in%20three%20%28all%20grade-2%29.%20Childhood%20ovarian%20NS-GCTs%20have%20an%20excellent%20prognosis%20with%20few%20late%20effects.%20The%20low-intensive%20etoposide-free%20VBP%20regimen%20could%20be%20an%20alternative%20in%20children%20with%20IR%20disease%20especially%20in%20cases%20of%20tumor%20rupture.%20The%20risk%20of%20contralateral%20mature%20teratoma%20needs%20regular%20monitoring%20of%20the%20remaining%20ovary.%22%2C%22date%22%3A%222021-11-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fijc.33710%22%2C%22ISSN%22%3A%221097-0215%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222022-01-14T15%3A53%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22YWWFMRCH%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Singh%20et%20al.%22%2C%22parsedDate%22%3A%222021-10-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESingh%2C%20Preeti%2C%20Maninder%20Heer%2C%20Anastasia%20Resteu%2C%20Aneta%20Mikulasova%2C%20Mojgan%20Reza%2C%20Laetitia%20Largeaud%2C%20Stephanie%20Dufrechou%2C%20et%20al.%20%26%23x201C%3BGATA2%20Deficiency%20Phenotype%20Associated%20with%20Tandem%20Duplication%20GATA2%20and%20Over-Expression%20of%20GATA2-AS1.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%2C%20October%2012%2C%202021%2C%20bloodadvances.2021005217.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021005217%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2021005217%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22GATA2%20deficiency%20phenotype%20associated%20with%20tandem%20duplication%20GATA2%20and%20over-expression%20of%20GATA2-AS1%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Preeti%22%2C%22lastName%22%3A%22Singh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maninder%22%2C%22lastName%22%3A%22Heer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anastasia%22%2C%22lastName%22%3A%22Resteu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aneta%22%2C%22lastName%22%3A%22Mikulasova%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mojgan%22%2C%22lastName%22%3A%22Reza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nais%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rachel%20E.%22%2C%22lastName%22%3A%22Dickinson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacinta%22%2C%22lastName%22%3A%22Bustamante%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22B%5Cu00e9n%5Cu00e9dicte%22%2C%22lastName%22%3A%22Neven%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Venetia%22%2C%22lastName%22%3A%22Bigley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Rico%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marlene%22%2C%22lastName%22%3A%22Pasquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthew%22%2C%22lastName%22%3A%22Collin%22%7D%5D%2C%22abstractNote%22%3A%22A%203-year%20old%20girl%20of%20non-consanguineous%20healthy%20parents%20presented%20with%20cervical%20and%20mediastinal%20lymphadenopathy%20due%20to%20Mycobacterium%20fortuitum%20infection.%20Routine%20blood%20analysis%20showed%20normal%20hemoglobin%2C%20neutrophils%20and%20platelets%20but%20profound%20mononuclear%20cell%20deficiency%20%28monocytes%20%3C0.1x109%5C%2FL%3B%20B%20cells%2078%5C%2F%5Cu00b5L%3B%20NK%20cells%2048%5C%2F%5Cu00b5L%29.%20A%20548%2C902bp%20region%20containing%20GATA2%20was%20sequenced%20by%20targeted%20capture%20and%20deep%20sequencing.%20This%20revealed%20a%20de%20novo%20187Kb%20duplication%20of%20the%20entire%20GATA2%20locus%2C%20containing%20a%20maternally%20inherited%20copy%20number%20variation%20deletion%20of%2025Kb%20%28GRCh37%3A%20esv2725896%20and%20nsv513733%29.%20Many%20GATA2-associated%20phenotypes%20have%20been%20attributed%20to%20amino%20acid%20substitution%2C%20frameshift%5C%2Fdeletion%2C%20loss%20of%20intronic%20enhancer%20function%20or%20aberrant%20splicing.%20Gene%20deletion%20has%20been%20described%20but%20other%20structural%20variation%20has%20not%20been%20reported%20in%20the%20germline%20configuration.%20In%20this%20case%2C%20duplication%20of%20the%20GATA2%20locus%20was%20paradoxically%20associated%20with%20skewed%2C%20diminished%20expression%20of%20GATA2%20mRNA%20and%20loss%20of%20GATA2%20protein.%20Chimeric%20RNA%20fusion%20transcripts%20were%20not%20detected.%20A%20possible%20mechanism%20involves%20increased%20transcription%20of%20the%20anti-sense%20long-non-coding%20%28lnc%29RNA%20GATA2-AS1%20%28RP11-472.220%29%20which%20was%20increased%20several-fold.%20This%20case%20further%20highlights%20that%20evaluation%20of%20the%20allele%20count%20is%20essential%20in%20any%20case%20of%20suspected%20GATA2-related%20syndrome.%22%2C%22date%22%3A%222021-10-12%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2021005217%22%2C%22ISSN%22%3A%222473-9537%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-11-22T16%3A40%3A17Z%22%7D%7D%2C%7B%22key%22%3A%2232NDPVRC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Magnol%20et%20al.%22%2C%22parsedDate%22%3A%222021-09-01%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EMagnol%2C%20Marion%2C%20Loukianos%20Couvaras%2C%20Yannick%20Degbo%26%23xE9%3B%2C%20Eric%20Delabesse%2C%20Cristina%20Bulai-Livideanu%2C%20Adeline%20Ruyssen-Witrand%2C%20and%20Arnaud%20Constantin.%20%26%23x201C%3BVEXAS%20Syndrome%20in%20a%20Patient%20with%20Previous%20Spondyloarthritis%20with%20a%20Favourable%20Response%20to%20Intravenous%20Immunoglobulin%20and%20Anti-IL17%20Therapy.%26%23x201D%3B%20%3Ci%3ERheumatology%20%28Oxford%2C%20England%29%3C%5C%2Fi%3E%2060%2C%20no.%209%20%28September%201%2C%202021%29%3A%20e314%26%23x2013%3B15.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Frheumatology%5C%2Fkeab211%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1093%5C%2Frheumatology%5C%2Fkeab211%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22VEXAS%20syndrome%20in%20a%20patient%20with%20previous%20spondyloarthritis%20with%20a%20favourable%20response%20to%20intravenous%20immunoglobulin%20and%20anti-IL17%20therapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Magnol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loukianos%22%2C%22lastName%22%3A%22Couvaras%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yannick%22%2C%22lastName%22%3A%22Degbo%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cristina%22%2C%22lastName%22%3A%22Bulai-Livideanu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adeline%22%2C%22lastName%22%3A%22Ruyssen-Witrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Constantin%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-09-01%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1093%5C%2Frheumatology%5C%2Fkeab211%22%2C%22ISSN%22%3A%221462-0332%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-10-29T14%3A21%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22KIXX2FVJ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bouvier%20et%20al.%22%2C%22parsedDate%22%3A%222021-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBouvier%2C%20Anne%2C%20Jean-Fran%26%23xE7%3Bois%20Hamel%2C%20Jacques%20Delaunay%2C%20Eric%20Delabesse%2C%20Pierre-Yves%20Dumas%2C%20Marie-Pierre%20Ledoux%2C%20Pierre%20Peterlin%2C%20et%20al.%20%26%23x201C%3BMolecular%20Classification%20and%20Prognosis%20in%20Younger%20Adults%20with%20Acute%20Myeloid%20Leukemia%20and%20Intermediate-Risk%20Cytogenetics%20Treated%20or%20Not%20by%20Gemtuzumab%20Ozogamycin%3A%20Final%20Results%20of%20the%20GOELAMS%5C%2FFILO%20Acute%20Myeloid%20Leukemia%202006-Intermediate-Risk%20Trial.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Haematology%3C%5C%2Fi%3E%20107%2C%20no.%201%20%28July%202021%29%3A%20111%26%23x2013%3B21.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13626%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13626%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Molecular%20classification%20and%20prognosis%20in%20younger%20adults%20with%20acute%20myeloid%20leukemia%20and%20intermediate-risk%20cytogenetics%20treated%20or%20not%20by%20gemtuzumab%20ozogamycin%3A%20Final%20results%20of%20the%20GOELAMS%5C%2FFILO%20acute%20myeloid%20leukemia%202006-intermediate-risk%20trial%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Bouvier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Hamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jacques%22%2C%22lastName%22%3A%22Delaunay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Pierre%22%2C%22lastName%22%3A%22Ledoux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Peterlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabrielle%22%2C%22lastName%22%3A%22Roth%20Guepin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%20Eric%22%2C%22lastName%22%3A%22Bulabois%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%20Pilar%22%2C%22lastName%22%3A%22Gallego%20Hernanz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ga%5Cu00eblle%22%2C%22lastName%22%3A%22Guillerm%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Guieze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yosr%22%2C%22lastName%22%3A%22Hicheri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lestine%22%2C%22lastName%22%3A%22Simand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chantal%22%2C%22lastName%22%3A%22Himberlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Hunault-Berger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Jourdan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Denis%22%2C%22lastName%22%3A%22Caillot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Dorvaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Tavernier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Daguindau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Banos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Ojeda-Uribe%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Gyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magda%22%2C%22lastName%22%3A%22Alexis%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Marolleau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascal%22%2C%22lastName%22%3A%22Turlure%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Bouscary%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Humbrecht%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hac%5Cu00e8ne%22%2C%22lastName%22%3A%22Zerazhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Christine%22%2C%22lastName%22%3A%22B%5Cu00e9n%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Carre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Ifrah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Blanchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Vey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Cornillet-Lef%5Cu00e8bvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22French%20Innovative%20Leukemia%20Organization%22%7D%5D%2C%22abstractNote%22%3A%22In%20this%20randomized%20phase%203%20study%2C%20the%20FILO%20group%20tested%20whether%20the%20addition%20of%206%5Cu00a0mg%5C%2Fm2%20of%20gemtuzumab%20ozogamycin%20%28GO%29%20to%20standard%20chemotherapy%20could%20improve%20outcome%20of%20younger%20patients%20with%20de%20novo%20acute%20myeloid%20leukemia%20%28AML%29%20and%20intermediate-risk%20cytogenetics.%20GO%20arm%20was%20prematurely%20closed%20after%20254%20inclusions%20because%20of%20toxicity.%20A%20similar%20complete%20remission%20rate%20was%20observed%20in%20both%20arms.%20Neither%20event-free%20survival%20nor%20overall%20survival%20were%20improved%20by%20GO%20in%20younger%20AML%20patients%20%28%3C60%5Cu00a0years%29%20ineligible%20for%20allogeneic%20stem-cell%20transplantation.%20%28P%5Cu00a0%3D%5Cu00a0.086%3B%20P%5Cu00a0%3D%5Cu00a0.149%2C%20respectively%29.%20Using%20unsupervised%20hierarchical%20clustering%20based%20on%20mutational%20analysis%20of%20seven%20genes%20%28NPM1%2C%20FLT3-ITD%2C%20CEBPA%2C%20DNMT3A%2C%20IDH1%2C%20IDH2%2C%20and%20ASXL1%29%2C%20six%20clusters%20of%20patients%20with%20significant%20different%20outcome%20were%20identified.%20Five%20clusters%20were%20based%20on%20FLT3-ITD%2C%20NPM1%2C%20and%20CEBPA%20mutations%20as%20well%20as%20epigenetic%20modifiers%20%28DNMT3A%2C%20IDH1%5C%2F2%2C%20ASXL1%29%2C%20whereas%20the%20last%20cluster%2C%20representing%2025%25%20of%20patients%2C%20had%20no%20mutation%20and%20intermediate%20risk.%20One%20cluster%20isolated%20FLT3-ITD%20mutations%20with%20higher%20allelic%20ratio%20and%20a%20very%20poor%20outcome.%20The%20addition%20of%20GO%20had%20no%20impact%20in%20these%20molecular%20clusters.%20Although%20not%20conclusive%20for%20GO%20impact%20in%20AML%20patients%20%3C60%5Cu00a0years%2C%20this%20study%20provides%20a%20molecular%20classification%20that%20distinguishes%20six%20AML%20clusters%20influencing%20prognosis%20in%20younger%20AML%20patients%20with%20intermediate-risk%20cytogenetic.%22%2C%22date%22%3A%222021-07%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fejh.13626%22%2C%22ISSN%22%3A%221600-0609%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A31%3A17Z%22%7D%7D%2C%7B%22key%22%3A%2254EB2K73%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Largeaud%20et%20al.%22%2C%22parsedDate%22%3A%222021-05%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELargeaud%2C%20Laetitia%2C%20Pascale%20Cornillet-Lefebvre%2C%20Jean-Fran%26%23xE7%3Bois%20Hamel%2C%20Pierre-Yves%20Dumas%2C%20Na%26%23xEF%3Bs%20Prade%2C%20St%26%23xE9%3Bphanie%20Dufrechou%2C%20Julien%20Plenecassagnes%2C%20et%20al.%20%26%23x201C%3BLomustine%20Is%20Beneficial%20to%20Older%20AML%20with%20ELN2017%20Adverse%20Risk%20Profile%20and%20Intermediate%20Karyotype%3A%20A%20FILO%20Study.%26%23x201D%3B%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2035%2C%20no.%205%20%28May%202021%29%3A%201291%26%23x2013%3B1300.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-020-01031-1%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-020-01031-1%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Lomustine%20is%20beneficial%20to%20older%20AML%20with%20ELN2017%20adverse%20risk%20profile%20and%20intermediate%20karyotype%3A%20a%20FILO%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Cornillet-Lefebvre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Hamel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Plenecassagnes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Blanchet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Banos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20C.%22%2C%22lastName%22%3A%22B%5Cu00e9n%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bonmati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc%20Matthieu%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Gui%5Cu00e8ze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lamya%22%2C%22lastName%22%3A%22Haddaoui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Hunault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Christophe%22%2C%22lastName%22%3A%22Ianotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Jourdan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Ojeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Peterlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Vey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hacene%22%2C%22lastName%22%3A%22Zerazhi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hicheri%22%2C%22lastName%22%3A%22Yosr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ariane%22%2C%22lastName%22%3A%22Mineur%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Yves%22%2C%22lastName%22%3A%22Cahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Norbert%22%2C%22lastName%22%3A%22Ifrah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22French%20Innovative%20Leukemia%20Organization%20%28FILO%29%22%7D%5D%2C%22abstractNote%22%3A%22We%20previously%20reported%20the%20benefit%20of%20lomustine%20addition%20to%20conventional%20chemotherapy%20in%20older%20acute%20myeloid%20leukemias%20with%20nonadverse%20chromosomal%20aberrations%20in%20the%20LAM-SA%202007%20randomized%20clinical%20trial%20%28NCT00590837%29.%20A%20molecular%20analysis%20of%2052%20genes%20performed%20in%20330%20patients%20included%20in%20this%20trial%2C%20163%20patients%20being%20treated%20with%20lomustine%20in%20combination%20with%20idarubicin%20and%20cytarabine%20and%20167%20without%20lomustine%2C%20identified%201088%20mutations%20with%20an%20average%20of%203.3%20mutations%20per%20patient.%20NPM1%2C%20FLT3%2C%20and%20DNMT3A%20were%20the%20most%20frequently%20mutated%20genes.%20A%20putative%20therapeutic%20target%20was%20identified%20in%20178%20patients%20%2854%25%29.%20Among%20five%20molecular%20classifications%20analyzed%2C%20the%20ELN2017%20risk%20classification%20has%20the%20stronger%20association%20with%20the%20clinical%20evolution.%20Patients%20not%20treated%20with%20lomustine%20have%20an%20expected%20survival%20prognosis%20in%20agreement%20with%20this%20classification%20regarding%20the%20overall%20and%20event-free%20survivals.%20In%20strong%20contrast%2C%20lomustine%20erased%20the%20ELN2017%20classification%20prognosis.%20The%20benefit%20of%20lomustine%20in%20nonadverse%20chromosomal%20aberrations%20was%20restricted%20to%20patients%20with%20RUNX1%2C%20ASXL1%2C%20TP53%2C%20and%20FLT3-ITDhigh%5C%2FNPM1WT%20mutations%20in%20contrast%20to%20the%20intermediate%20and%20favorable%20ELN2017%20patients.%20This%20post-hoc%20analysis%20identified%20a%20subgroup%20of%20fit%20elderly%20AML%20patients%20with%20intermediate%20cytogenetics%20and%20molecular%20markers%20who%20may%20benefit%20from%20lomustine%20addition%20to%20intensive%20chemotherapy.%22%2C%22date%22%3A%222021-05%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-020-01031-1%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-11-15T17%3A46%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22TFPU6SRV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Duployez%20et%20al.%22%2C%22parsedDate%22%3A%222021-03-11%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDuployez%2C%20Nicolas%2C%20Laura%20A.%20Jamrog%2C%20Vincent%20Fregona%2C%20Camille%20Hamelle%2C%20Laur%26%23xE8%3Bne%20Fenwarth%2C%20Sophie%20Lejeune%2C%20Nathalie%20Helevaut%2C%20et%20al.%20%26%23x201C%3BGermline%20PAX5%20Mutation%20Predisposes%20to%20Familial%20B-Cell%20Precursor%20Acute%20Lymphoblastic%20Leukemia.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20137%2C%20no.%2010%20%28March%2011%2C%202021%29%3A%201424%26%23x2013%3B28.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020005756%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020005756%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Germline%20PAX5%20mutation%20predisposes%20to%20familial%20B-cell%20precursor%20acute%20lymphoblastic%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Duployez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laura%20A.%22%2C%22lastName%22%3A%22Jamrog%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Fregona%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Hamelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laur%5Cu00e8ne%22%2C%22lastName%22%3A%22Fenwarth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sophie%22%2C%22lastName%22%3A%22Lejeune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Helevaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandrine%22%2C%22lastName%22%3A%22Geffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Caillault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alice%22%2C%22lastName%22%3A%22Marceau-Renaut%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Poulain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Roche-Lestienne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sylvie%22%2C%22lastName%22%3A%22H%5Cu00e9brard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Berthon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brigitte%22%2C%22lastName%22%3A%22Nelken%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jos%5Cu00e9%22%2C%22lastName%22%3A%22Fernandes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9line%22%2C%22lastName%22%3A%22Villenet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Figeac%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Gerby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Preudhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyril%22%2C%22lastName%22%3A%22Broccardo%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222021-03-11%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2020005756%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-11-15T17%3A46%3A36Z%22%7D%7D%2C%7B%22key%22%3A%22UJZIDDDY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Cartel%20et%20al.%22%2C%22parsedDate%22%3A%222021-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ECartel%2C%20Ma%26%23xEB%3Blle%2C%20Pierre-Luc%20Mouchel%2C%20Mathilde%20Gotan%26%23xE8%3Bgre%2C%20Laure%20David%2C%20Sarah%20Bertoli%2C%20V%26%23xE9%3Bronique%20Mansat-De%20Mas%2C%20Arnaud%20Besson%2C%20Jean-Emmanuel%20Sarry%2C%20St%26%23xE9%3Bphane%20Manenti%2C%20and%20Christine%20Didier.%20%26%23x201C%3BInhibition%20of%20Ubiquitin-Specific%20Protease%207%20Sensitizes%20Acute%20Myeloid%20Leukemia%20to%20Chemotherapy.%26%23x201D%3B%20%3Ci%3ELeukemia%3C%5C%2Fi%3E%2035%2C%20no.%202%20%28February%202021%29%3A%20417%26%23x2013%3B32.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-020-0878-x%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41375-020-0878-x%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Inhibition%20of%20ubiquitin-specific%20protease%207%20sensitizes%20acute%20myeloid%20leukemia%20to%20chemotherapy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ma%5Cu00eblle%22%2C%22lastName%22%3A%22Cartel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Luc%22%2C%22lastName%22%3A%22Mouchel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Gotan%5Cu00e8gre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laure%22%2C%22lastName%22%3A%22David%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Mansat-De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Besson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Emmanuel%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Manenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Didier%22%7D%5D%2C%22abstractNote%22%3A%22Resistance%20of%20acute%20myeloid%20leukemia%20%28AML%29%20to%20therapeutic%20agents%20is%20frequent.%20Consequently%2C%20the%20mechanisms%20leading%20to%20this%20resistance%20must%20be%20understood%20and%20addressed.%20In%20this%20paper%2C%20we%20demonstrate%20that%20inhibition%20of%20deubiquitinylase%20USP7%20significantly%20reduces%20cell%20proliferation%20in%20vitro%20and%20in%20vivo%2C%20blocks%20DNA%20replication%20progression%20and%20increases%20cell%20death%20in%20AML.%20Transcriptomic%20dataset%20analyses%20reveal%20that%20a%20USP7%20gene%20signature%20is%20highly%20enriched%20in%20cells%20from%20AML%20patients%20at%20relapse%2C%20as%20well%20as%20in%20residual%20blasts%20from%20patient-derived%20xenograft%20%28PDX%29%20models%20treated%20with%20clinically%20relevant%20doses%20of%20cytarabine%2C%20which%20indicates%20a%20relationship%20between%20USP7%20expression%20and%20resistance%20to%20therapy.%20Accordingly%2C%20single-cell%20analysis%20of%20AML%20patient%20samples%20at%20relapse%20versus%20at%20diagnosis%20showed%20that%20a%20gene%20signature%20of%20the%20pre-existing%20subpopulation%20responsible%20for%20relapse%20is%20enriched%20in%20transcriptomes%20of%20patients%20with%20a%20high%20USP7%20level.%20Furthermore%2C%20we%20found%20that%20USP7%20interacts%20and%20modulates%20CHK1%20protein%20levels%20and%20functions%20in%20AML.%20Finally%2C%20we%20demonstrated%20that%20USP7%20inhibition%20acts%20in%20synergy%20with%20cytarabine%20to%20kill%20AML%20cell%20lines%20and%20primary%20cells%20of%20patients%20with%20high%20USP7%20levels.%20Altogether%2C%20these%20data%20demonstrate%20that%20USP7%20is%20both%20a%20marker%20of%20resistance%20to%20chemotherapy%20and%20a%20potential%20therapeutic%20target%20in%20overcoming%20resistance%20to%20treatment.%22%2C%22date%22%3A%222021-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41375-020-0878-x%22%2C%22ISSN%22%3A%221476-5551%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22WVCHCN8C%22%2C%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-16T13%3A59%3A19Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Récher, Christian, Christoph Röllig, Emilie Bérard, Sarah Bertoli, Pierre-Yves Dumas, Suzanne Tavitian, Michael Kramer, et al. “Long-Term Survival after Intensive Chemotherapy or Hypomethylating Agents in AML Patients Aged 70 Years and Older: A Large Patient Data Set Study from European Registries.” Leukemia<\/i>, November 13, 2021. https:\/\/doi.org\/10.1038\/s41375-021-01425-9<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Galtier, Jean, Camille Alric, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Audrey Bidet, Eric Delabesse, et al. “Intermediate-Dose Cytarabine or Standard-Dose Cytarabine plus Single-Dose Anthracycline as Post-Remission Therapy in Older Patients with Acute Myeloid Leukemia: Impact on Health Care Resource Consumption and Outcomes.” Blood Cancer Journal<\/i> 11, no. 11 (November 13, 2021): 180. https:\/\/doi.org\/10.1038\/s41408-021-00551-y<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Fregona, Vincent, Manon Bayet, and Bastien Gerby. “Oncogene-Induced Reprogramming in Acute Lymphoblastic Leukemia: Towards Targeted Therapy of Leukemia-Initiating Cells.” Cancers<\/i> 13, no. 21 (November 2, 2021): 5511. https:\/\/doi.org\/10.3390\/cancers13215511<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Pavone, Rossana, Hélène Pacquement, Marlène Pasquet, Hélène Sudour-Bonnange, Fédéric Hameury, Sabine Sarnacki, Pascal Chastagner, et al. “Childhood Ovarian Nonseminomatous Germ Cell Tumors: A Highly Curable Disease with Few Long-Term Treatment-Related Toxicities-Results of the French TGM95 Study.” International Journal of Cancer<\/i> 149, no. 9 (November 1, 2021): 1705–12. https:\/\/doi.org\/10.1002\/ijc.33710<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Singh, Preeti, Maninder Heer, Anastasia Resteu, Aneta Mikulasova, Mojgan Reza, Laetitia Largeaud, Stephanie Dufrechou, et al. “GATA2 Deficiency Phenotype Associated with Tandem Duplication GATA2 and Over-Expression of GATA2-AS1.” Blood Advances<\/i>, October 12, 2021, bloodadvances.2021005217. https:\/\/doi.org\/10.1182\/bloodadvances.2021005217<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Magnol, Marion, Loukianos Couvaras, Yannick Degboé, Eric Delabesse, Cristina Bulai-Livideanu, Adeline Ruyssen-Witrand, and Arnaud Constantin. “VEXAS Syndrome in a Patient with Previous Spondyloarthritis with a Favourable Response to Intravenous Immunoglobulin and Anti-IL17 Therapy.” Rheumatology (Oxford, England)<\/i> 60, no. 9 (September 1, 2021): e314–15. https:\/\/doi.org\/10.1093\/rheumatology\/keab211<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bouvier, Anne, Jean-François Hamel, Jacques Delaunay, Eric Delabesse, Pierre-Yves Dumas, Marie-Pierre Ledoux, Pierre Peterlin, et al. “Molecular Classification and Prognosis in Younger Adults with Acute Myeloid Leukemia and Intermediate-Risk Cytogenetics Treated or Not by Gemtuzumab Ozogamycin: Final Results of the GOELAMS\/FILO Acute Myeloid Leukemia 2006-Intermediate-Risk Trial.” European Journal of Haematology<\/i> 107, no. 1 (July 2021): 111–21. https:\/\/doi.org\/10.1111\/ejh.13626<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Largeaud, Laetitia, Pascale Cornillet-Lefebvre, Jean-François Hamel, Pierre-Yves Dumas, Naïs Prade, Stéphanie Dufrechou, Julien Plenecassagnes, et al. “Lomustine Is Beneficial to Older AML with ELN2017 Adverse Risk Profile and Intermediate Karyotype: A FILO Study.” Leukemia<\/i> 35, no. 5 (May 2021): 1291–1300. https:\/\/doi.org\/10.1038\/s41375-020-01031-1<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Duployez, Nicolas, Laura A. Jamrog, Vincent Fregona, Camille Hamelle, Laurène Fenwarth, Sophie Lejeune, Nathalie Helevaut, et al. “Germline PAX5 Mutation Predisposes to Familial B-Cell Precursor Acute Lymphoblastic Leukemia.” Blood<\/i> 137, no. 10 (March 11, 2021): 1424–28. https:\/\/doi.org\/10.1182\/blood.2020005756<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Cartel, Maëlle, Pierre-Luc Mouchel, Mathilde Gotanègre, Laure David, Sarah Bertoli, Véronique Mansat-De Mas, Arnaud Besson, Jean-Emmanuel Sarry, Stéphane Manenti, and Christine Didier. “Inhibition of Ubiquitin-Specific Protease 7 Sensitizes Acute Myeloid Leukemia to Chemotherapy.” Leukemia<\/i> 35, no. 2 (February 2021): 417–32. https:\/\/doi.org\/10.1038\/s41375-020-0878-x<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2020″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_font=”|600|||||||” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t9RREECEZ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2020<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 40076<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-f65a7e06c85482360332bd26c3e8bdeb%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22JCCXV4XZ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bories%20et%20al.%22%2C%22parsedDate%22%3A%222020-10-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBories%2C%20Pierre%2C%20Na%26%23xEF%3Bs%20Prade%2C%20St%26%23xE9%3Bphanie%20Lagarde%2C%20Bastien%20Cabarrou%2C%20Laetitia%20Largeaud%2C%20Julien%20Plenecassagnes%2C%20Isabelle%20Luquet%2C%20et%20al.%20%26%23x201C%3BImpact%20of%20TP53%20Mutations%20in%20Acute%20Myeloid%20Leukemia%20Patients%20Treated%20with%20Azacitidine.%26%23x201D%3B%20Edited%20by%20Francesco%20Bertolini.%20%3Ci%3EPLOS%20ONE%3C%5C%2Fi%3E%2015%2C%20no.%2010%20%28October%201%2C%202020%29%3A%20e0238795.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0238795%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1371%5C%2Fjournal.pone.0238795%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20TP53%20mutations%20in%20acute%20myeloid%20leukemia%20patients%20treated%20with%20azacitidine%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Cabarrou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Plenecassagnes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Filleron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Manon%22%2C%22lastName%22%3A%22Cassou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luc-Matthieu%22%2C%22lastName%22%3A%22Fornecker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9lestine%22%2C%22lastName%22%3A%22Simand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22Recher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22editor%22%2C%22firstName%22%3A%22Francesco%22%2C%22lastName%22%3A%22Bertolini%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-10-1%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1371%5C%2Fjournal.pone.0238795%22%2C%22ISSN%22%3A%221932-6203%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdx.plos.org%5C%2F10.1371%5C%2Fjournal.pone.0238795%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22NNPEGMWB%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dumas%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDumas%2C%20Pierre-Yves%2C%20Sarah%20Bertoli%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Thibaut%20Leguay%2C%20Suzanne%20Tavitian%2C%20Jean%20Galtier%2C%20Camille%20Alric%2C%20et%20al.%20%26%23x201C%3BDelivering%20HDAC%20over%203%20or%205%20Days%20as%20Consolidation%20in%20AML%20Impacts%20Health%20Care%20Resource%20Consumption%20but%20Not%20Outcome.%26%23x201D%3B%20%3Ci%3EBlood%20Advances%3C%5C%2Fi%3E%204%2C%20no.%2016%20%28August%2025%2C%202020%29%3A%203840%26%23x2013%3B49.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2020002511%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fbloodadvances.2020002511%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delivering%20HDAC%20over%203%20or%205%20days%20as%20consolidation%20in%20AML%20impacts%20health%20care%20resource%20consumption%20but%20not%20outcome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Galtier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Alric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lechevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9lo%5Cu00efse%22%2C%22lastName%22%3A%22Rey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Charlotte%22%2C%22lastName%22%3A%22de%20Grande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Postremission%20treatment%20is%20crucial%20to%20prevent%20relapse%20in%20acute%20myeloid%20leukemia%20%28AML%29.%20High-dose%20cytarabine%20delivered%20every%2012%20hours%20on%20days%201%2C%203%2C%20and%205%20%28HDAC-135%29%20is%20the%20standard%20of%20care%20for%20younger%20adult%20patients%20with%20AML.%20Although%20this%20standard%20has%20been%20unsuccessfully%20challenged%20by%20other%20treatment%20regimens%2C%20including%20multiagent%20chemotherapy%2C%20the%20timing%20of%20HDAC%20administration%20has%20attracted%20little%20attention.%20Here%2C%20we%20retrospectively%20compared%20the%20safety%2C%20efficacy%2C%20and%20health%20care%20resource%20consumption%20associated%20with%20HDAC-135%20and%20another%20standard%2C%20condensed%20HDAC-123%20regimen%2C%20as%20consolidation%20treatment%20in%20younger%20AML%20patients%20in%20first%20complete%20response.%20This%20study%20included%20221%20patients%20%28median%20age%2C%2046.6%20years%3B%20range%2C%2018-60%20years%29.%20HDAC-123%20and%20HDAC-135%20were%20used%20in%2092%20and%20129%20patients%2C%20respectively.%20Both%20regimens%20were%20associated%20with%20similar%20rates%20of%20relapse-free%20survival%2C%20cumulative%20incidence%20of%20relapse%2C%20nonrelapse%20mortality%2C%20and%20overall%20survival%2C%20including%20in%20core%20binding%20factor%20AML%20subgroup%20in%20which%20levels%20of%20minimal%20residual%20disease%20reduction%20were%20similar%20in%20both%20schedules.%20Hematological%20recovery%20times%20regarding%20neutrophils%20and%20platelets%20were%20significantly%20shorter%20in%20patients%20receiving%20HDAC-123%2C%20with%20an%20average%20difference%20of%203%20to%204%20days%20for%20each%20consolidation%20cycle.%20The%20total%20duration%20of%20hospitalization%20for%20the%20whole%20postremission%20program%20was%20shorter%20with%20HDAC-123%20%2832%20days%3B%20interquartile%20ratio%20%5BIQR%5D%2C%2022.0%2C36.5%29%20compared%20with%20HDAC-135%20%2841%20days%3B%20IQR%2C%2030.5%2C%2050.0%29%20%28P%20%26lt%3B%20.0001%29.%20In%20conclusion%2C%20the%20condensed%20HDAC-123%20regimen%20induced%20faster%20hematological%20recovery%20and%20therefore%20significantly%20reduced%20the%20length%20of%20hospital%20stay%20without%20affecting%20treatment%20response%20or%20outcome%20in%20younger%20AML%20patients.%22%2C%22date%22%3A%222020-08-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1182%5C%2Fbloodadvances.2020002511%22%2C%22ISSN%22%3A%222473-9529%2C%202473-9537%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fashpublications.org%5C%2Fbloodadvances%5C%2Farticle%5C%2F4%5C%2F16%5C%2F3840%5C%2F461785%5C%2FDelivering-HDAC-over-3-or-5-days-as-consolidation%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22JP2ZMWZQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fagnan%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFagnan%2C%20Alexandre%2C%20Frederik%20Otzen%20Bagger%2C%20Maria-Riera%20Piqu%26%23xE9%3B-Borr%26%23xE0%3Bs%2C%20Cathy%20Ignacimouttou%2C%20Alexis%20Caulier%2C%20C%26%23xE9%3Bcile%20K.%20Lopez%2C%20Elie%20Robert%2C%20et%20al.%20%26%23x201C%3BHuman%20Erythroleukemia%20Genetics%20and%20Transcriptomes%20Identify%20Master%20Transcription%20Factors%20as%20Functional%20Disease%20Drivers.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20136%2C%20no.%206%20%28August%206%2C%202020%29%3A%20698%26%23x2013%3B714.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2019003062%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2019003062%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Human%20erythroleukemia%20genetics%20and%20transcriptomes%20identify%20master%20transcription%20factors%20as%20functional%20disease%20drivers%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Fagnan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frederik%20Otzen%22%2C%22lastName%22%3A%22Bagger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria-Riera%22%2C%22lastName%22%3A%22Piqu%5Cu00e9-Borr%5Cu00e0s%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%22%2C%22lastName%22%3A%22Ignacimouttou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%22%2C%22lastName%22%3A%22Caulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%20K.%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Uzan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Gelsi-Boyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zakia%22%2C%22lastName%22%3A%22Aid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Thirant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ute%22%2C%22lastName%22%3A%22Moll%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samantha%22%2C%22lastName%22%3A%22Tauchmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Amina%22%2C%22lastName%22%3A%22Kurtovic-Kozaric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jaroslaw%22%2C%22lastName%22%3A%22Maciejewski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christine%22%2C%22lastName%22%3A%22Dierks%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Orietta%22%2C%22lastName%22%3A%22Spinelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Salmoiraghi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Pabst%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kazuya%22%2C%22lastName%22%3A%22Shimoda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Virginie%22%2C%22lastName%22%3A%22Deleuze%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H%5Cu00e9l%5Cu00e8ne%22%2C%22lastName%22%3A%22Lapillonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Connor%22%2C%22lastName%22%3A%22Sweeney%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Betty%22%2C%22lastName%22%3A%22Leite%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zahra%22%2C%22lastName%22%3A%22Kadri%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Malinge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22de%20Botton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Micol%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Kile%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%20L.%22%2C%22lastName%22%3A%22Carmichael%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ilaria%22%2C%22lastName%22%3A%22Iacobucci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charles%20G.%22%2C%22lastName%22%3A%22Mullighan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Carroll%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Valent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%20A.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paresh%22%2C%22lastName%22%3A%22Vyas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniel%22%2C%22lastName%22%3A%22Birnbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eduardo%22%2C%22lastName%22%3A%22Anguita%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lo%5Cu00efc%22%2C%22lastName%22%3A%22Gar%5Cu00e7on%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Soler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juerg%22%2C%22lastName%22%3A%22Schwaller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Mercher%22%7D%5D%2C%22abstractNote%22%3A%22Abstract%5Cn%20%20%20%20%20%20%20%20%20%20%20%20Acute%20erythroleukemia%20%28AEL%20or%20acute%20myeloid%20leukemia%20%5BAML%5D-M6%29%20is%20a%20rare%20but%20aggressive%20hematologic%20malignancy.%20Previous%20studies%20showed%20that%20AEL%20leukemic%20cells%20often%20carry%20complex%20karyotypes%20and%20mutations%20in%20known%20AML-associated%20oncogenes.%20To%20better%20define%20the%20underlying%20molecular%20mechanisms%20driving%20the%20erythroid%20phenotype%2C%20we%20studied%20a%20series%20of%2033%20AEL%20samples%20representing%203%20genetic%20AEL%20subgroups%20including%20TP53-mutated%2C%20epigenetic%20regulator-mutated%20%28eg%2C%20DNMT3A%2C%20TET2%2C%20or%20IDH2%29%2C%20and%20undefined%20cases%20with%20low%20mutational%20burden.%20We%20established%20an%20erythroid%20vs%20myeloid%20transcriptome-based%20space%20in%20which%2C%20independently%20of%20the%20molecular%20subgroup%2C%20the%20majority%20of%20the%20AEL%20samples%20exhibited%20a%20unique%20mapping%20different%20from%20both%20non-M6%20AML%20and%20myelodysplastic%20syndrome%20samples.%20Notably%2C%20%26gt%3B25%25%20of%20AEL%20patients%2C%20including%20in%20the%20genetically%20undefined%20subgroup%2C%20showed%20aberrant%20expression%20of%20key%20transcriptional%20regulators%2C%20including%20SKI%2C%20ERG%2C%20and%20ETO2.%20Ectopic%20expression%20of%20these%20factors%20in%20murine%20erythroid%20progenitors%20blocked%20in%20vitro%20erythroid%20differentiation%20and%20led%20to%20immortalization%20associated%20with%20decreased%20chromatin%20accessibility%20at%20GATA1-binding%20sites%20and%20functional%20interference%20with%20GATA1%20activity.%20In%20vivo%20models%20showed%20development%20of%20lethal%20erythroid%2C%20mixed%20erythroid%5C%2Fmyeloid%2C%20or%20other%20malignancies%20depending%20on%20the%20cell%20population%20in%20which%20AEL-associated%20alterations%20were%20expressed.%20Collectively%2C%20our%20data%20indicate%20that%20AEL%20is%20a%20molecularly%20heterogeneous%20disease%20with%20an%20erythroid%20identity%20that%20results%20in%20part%20from%20the%20aberrant%20activity%20of%20key%20erythroid%20transcription%20factors%20in%20hematopoietic%20stem%20or%20progenitor%20cells.%22%2C%22date%22%3A%222020-08-6%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2019003062%22%2C%22ISSN%22%3A%220006-4971%2C%201528-0020%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fashpublications.org%5C%2Fblood%5C%2Farticle%5C%2F136%5C%2F6%5C%2F698%5C%2F454702%5C%2FHuman-erythroleukemia-genetics-and-transcriptomes%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A26Z%22%7D%7D%2C%7B%22key%22%3A%22U69QEGVR%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Rohmer%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-28%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ERohmer%2C%20Julien%2C%20Am%26%23xE9%3Blie%20Couteau%26%23x2010%3BChardon%2C%20Julie%20Trichereau%2C%20Kewin%20Panel%2C%20Cyrielle%20Gesquiere%2C%20Raouf%20Ben%20Abdelali%2C%20Audrey%20Bidet%2C%20et%20al.%20%26%23x201C%3BEpidemiology%2C%20Clinical%20Picture%20and%20Long%26%23x2010%3Bterm%20Outcomes%20of%20FIP1L1%26%23x2010%3BPDGFRA%26%23x2010%3Bpositive%20Myeloid%20Neoplasm%20with%20Eosinophilia%3A%20Data%20from%20151%20Patients.%26%23x201D%3B%20%3Ci%3EAmerican%20Journal%20of%20Hematology%3C%5C%2Fi%3E%2C%20July%2028%2C%202020%2C%20ajh.25945.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fajh.25945%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fajh.25945%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Epidemiology%2C%20clinical%20picture%20and%20long%5Cu2010term%20outcomes%20of%20FIP1L1%5Cu2010PDGFRA%5Cu2010positive%20myeloid%20neoplasm%20with%20eosinophilia%3A%20data%20from%20151%20patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julien%22%2C%22lastName%22%3A%22Rohmer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Am%5Cu00e9lie%22%2C%22lastName%22%3A%22Couteau%5Cu2010Chardon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Julie%22%2C%22lastName%22%3A%22Trichereau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kewin%22%2C%22lastName%22%3A%22Panel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cyrielle%22%2C%22lastName%22%3A%22Gesquiere%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raouf%20Ben%22%2C%22lastName%22%3A%22Abdelali%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010S%5Cu00e9bastien%22%2C%22lastName%22%3A%22Blad%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010Michel%22%2C%22lastName%22%3A%22Cayuela%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Cony%5Cu2010Makhoul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vincent%22%2C%22lastName%22%3A%22Cottin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mika%5Cu00ebl%22%2C%22lastName%22%3A%22Ebbo%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Fain%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascale%22%2C%22lastName%22%3A%22Flandrin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lionel%22%2C%22lastName%22%3A%22Galicier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Godon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Grardel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lien%22%2C%22lastName%22%3A%22Guffroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohamed%22%2C%22lastName%22%3A%22Hamidou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Hunault%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Lengline%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Faustine%22%2C%22lastName%22%3A%22Lhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ludovic%22%2C%22lastName%22%3A%22Lhermitte%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ir%5Cu00e8ne%22%2C%22lastName%22%3A%22Machelart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Mauvieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Catherine%22%2C%22lastName%22%3A%22Mohr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%5Cu2010Joelle%22%2C%22lastName%22%3A%22Mozicconacci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dina%22%2C%22lastName%22%3A%22Naguib%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franck%20E.%22%2C%22lastName%22%3A%22Nicolini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerome%22%2C%22lastName%22%3A%22Rey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Rousselot%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Louis%22%2C%22lastName%22%3A%22Terriou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Lef%5Cu00e8vre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claude%22%2C%22lastName%22%3A%22Preudhomme%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010Emmanuel%22%2C%22lastName%22%3A%22Kahn%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthieu%22%2C%22lastName%22%3A%22Groh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22CEREO%20and%20GBMHM%20collaborators%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22F%5Cu00e9lix%22%2C%22lastName%22%3A%22Ackermann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Didier%22%2C%22lastName%22%3A%22Adiko%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nuri%22%2C%22lastName%22%3A%22Ahwij%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Baruchel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Beal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maxime%22%2C%22lastName%22%3A%22Bemba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%20Beylot%22%2C%22lastName%22%3A%22barry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%20Beyne%22%2C%22lastName%22%3A%22rauzy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philip%22%2C%22lastName%22%3A%22Bielefeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Boisseau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Bonmati%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bernard%22%2C%22lastName%22%3A%22Bonnote%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%22%2C%22lastName%22%3A%22Borel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daoud%22%2C%22lastName%22%3A%22Bouredji%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Brignier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Brouillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22France%22%2C%22lastName%22%3A%22Campos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Carre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Chalayer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Claude%22%2C%22lastName%22%3A%22Chomel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Val%5Cu00e9rie%22%2C%22lastName%22%3A%22Coiteux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adrien%22%2C%22lastName%22%3A%22Contejean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Corby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phane%22%2C%22lastName%22%3A%22Darre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Viviane%22%2C%22lastName%22%3A%22Dubruille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9cile%20Audrey%22%2C%22lastName%22%3A%22Durel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abderrazak%20El%22%2C%22lastName%22%3A%22yamani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Etancelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Etienne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Philippe%22%2C%22lastName%22%3A%22Evon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuel%22%2C%22lastName%22%3A%22Gyan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Hachulla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marion%22%2C%22lastName%22%3A%22Hermet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Christophe%22%2C%22lastName%22%3A%22Ianotto%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lucas%22%2C%22lastName%22%3A%22Inchiappa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ibrahim%22%2C%22lastName%22%3A%22Jdid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Katayoun%22%2C%22lastName%22%3A%22Jondeau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Morgane%22%2C%22lastName%22%3A%22Joubert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fanny%22%2C%22lastName%22%3A%22Legrand%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Caroline%22%2C%22lastName%22%3A%22Lejeune%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claire%20Le%22%2C%22lastName%22%3A%22pendu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%22%2C%22lastName%22%3A%22Lidove%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Richard%22%2C%22lastName%22%3A%22Lemal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Limal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elena%22%2C%22lastName%22%3A%22Lopinet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fr%5Cu00e9deric%22%2C%22lastName%22%3A%22Maloisel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne%22%2C%22lastName%22%3A%22Marfaing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ibrahim%22%2C%22lastName%22%3A%22Marroun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Maurier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Muller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thierry%22%2C%22lastName%22%3A%22Muron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Ojeda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Romain%22%2C%22lastName%22%3A%22Paule%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Michel%22%2C%22lastName%22%3A%22Pignon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Rossi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Roumier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Sene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Sene%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%22%2C%22lastName%22%3A%22Simon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bohrane%22%2C%22lastName%22%3A%22Slama%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Felipe%22%2C%22lastName%22%3A%22Suarez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colas%22%2C%22lastName%22%3A%22Tcherakian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jose%20Miguel%22%2C%22lastName%22%3A%22Torregrosa%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Toussaint%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22R%5Cu00e9mi%22%2C%22lastName%22%3A%22Vatan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sorin%22%2C%22lastName%22%3A%22Visanica%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurent%22%2C%22lastName%22%3A%22Voilat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Marc%22%2C%22lastName%22%3A%22Zini%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-07-28%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1002%5C%2Fajh.25945%22%2C%22ISSN%22%3A%220361-8609%2C%201096-8652%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1002%5C%2Fajh.25945%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A13Z%22%7D%7D%2C%7B%22key%22%3A%222ZWCM8TS%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Dumas%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-24%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDumas%2C%20Pierre-Yves%2C%20Sarah%20Bertoli%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Laetitia%20Largeaud%2C%20Audrey%20Bidet%2C%20Eric%20Delabesse%2C%20Thibaut%20Leguay%2C%20et%20al.%20%26%23x201C%3BReal-World%20Outcomes%20of%20Patients%20with%20Refractory%20or%20Relapsed%20FLT3-ITD%20Acute%20Myeloid%20Leukemia%3A%20A%20Toulouse-Bordeaux%20DATAML%20Registry%20Study.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%208%20%28July%2024%2C%202020%29%3A%202044.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12082044%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12082044%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Real-World%20Outcomes%20of%20Patients%20with%20Refractory%20or%20Relapsed%20FLT3-ITD%20Acute%20Myeloid%20Leukemia%3A%20A%20Toulouse-Bordeaux%20DATAML%20Registry%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harmony%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Gadaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lechevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Charlotte%22%2C%22lastName%22%3A%22de%20Grande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22Two%20recent%20phase%203%20trials%20showed%20that%20outcomes%20for%20relapsed%5C%2Frefractory%20%28R%5C%2FR%29%20FLT3-mutated%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20may%20be%20improved%20by%20a%20single-agent%20tyrosine%20kinase%20inhibitor%20%28TKI%29%20%28i.e.%2C%20quizartinib%20or%20gilteritinib%29.%20In%20the%20current%20study%2C%20we%20retrospectively%20investigated%20the%20characteristics%20and%20real-world%20outcomes%20of%20R%5C%2FR%20FLT3-internal%20tandem%20duplication%20%28ITD%29%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20in%20the%20Toulouse-Bordeaux%20DATAML%20registry.%20In%20the%20study%2C%20we%20included%20316%20patients%20with%20FLT3-ITD%20AML%20that%20received%20intensive%20chemotherapy%20as%20a%20first-line%20treatment.%20The%20rate%20of%20complete%20remission%20%28CR%29%20or%20CR%20without%20hematological%20recovery%20%28CRi%29%20was%2075.2%25%2C%20and%20160%20patients%20were%20R%5C%2FR%20after%20a%20first-line%20TKI-free%20treatment%20%28n%20%3D%20294%29.%20Within%20the%20subgroup%20of%20R%5C%2FR%20patients%20that%20fulfilled%20the%20main%20criteria%20of%20the%20QUANTUM-R%20study%2C%2048.9%25%20received%20an%20intensive%20salvage%20regimen%3B%20none%20received%20hypomethylating%20agents%20or%20low-dose%20cytarabine.%20Among%20the%20R%5C%2FR%20FLT3-ITD%20AML%20patients%20with%20CR1%20durations%20%3C%206%20months%20who%20received%20intensive%20TKI-free%20treatment%2C%20the%20rate%20of%20CR%20or%20CRi%20after%20salvage%20chemotherapy%20was%2052.8%25%2C%20and%20these%20results%20allowed%20a%20bridge%20to%20be%20transplanted%20in%2039.6%25%20of%20cases.%20Finally%2C%20in%20this%20QUANTUM-R%20standard%20arm-matched%20cohort%2C%20the%20median%20overall%20survival%20%28OS%29%20was%207.0%20months%20and%201-%2C%203-%20and%205-year%20OS%20were%2030.2%25%2C%2023.7%25%20and%2021.4%25%2C%20respectively.%20To%20conclude%2C%20these%20real-world%20data%20show%20that%20the%20intensity%20of%20the%20second-line%20treatment%20likely%20affects%20response%20and%20transplantation%20rates.%20Furthermore%2C%20the%20results%20indicate%20that%20including%20patients%20with%20low-intensity%20regimens%2C%20such%20as%20low-dose%20cytarabine%20or%20hypomethylating%20agents%2C%20in%20the%20control%20arm%20of%20a%20phase%203%20trial%20may%20be%20counterproductive%20and%20could%20compromise%20the%20results%20of%20the%20study.%22%2C%22date%22%3A%222020-07-24%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12082044%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F8%5C%2F2044%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A14Z%22%7D%7D%2C%7B%22key%22%3A%22QV8UTYIP%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laurent%20et%20al.%22%2C%22parsedDate%22%3A%222020-07-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaurent%2C%20Anouchka%20P.%2C%20Aur%26%23xE9%3Blie%20Siret%2C%20Cathy%20Ignacimouttou%2C%20Kunjal%20Panchal%2C%20M%26%23x2019%3BBoyba%20Diop%2C%20Silvia%20Jenni%2C%20Yi-Chien%20Tsai%2C%20et%20al.%20%26%23x201C%3BConstitutive%20Activation%20of%20RAS%5C%2FMAPK%20Pathway%20Cooperates%20with%20Trisomy%2021%20and%20Is%20Therapeutically%20Exploitable%20in%20Down%20Syndrome%20B-Cell%20Leukemia.%26%23x201D%3B%20%3Ci%3EClinical%20Cancer%20Research%3A%20An%20Official%20Journal%20of%20the%20American%20Association%20for%20Cancer%20Research%3C%5C%2Fi%3E%2026%2C%20no.%2013%20%28July%201%2C%202020%29%3A%203307%26%23x2013%3B18.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-19-3519%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F1078-0432.CCR-19-3519%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Constitutive%20Activation%20of%20RAS%5C%2FMAPK%20Pathway%20Cooperates%20with%20Trisomy%2021%20and%20Is%20Therapeutically%20Exploitable%20in%20Down%20Syndrome%20B-cell%20Leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anouchka%20P.%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Siret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cathy%22%2C%22lastName%22%3A%22Ignacimouttou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kunjal%22%2C%22lastName%22%3A%22Panchal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%27Boyba%22%2C%22lastName%22%3A%22Diop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Silvia%22%2C%22lastName%22%3A%22Jenni%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yi-Chien%22%2C%22lastName%22%3A%22Tsai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Roos-Weil%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zakia%22%2C%22lastName%22%3A%22Aid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nais%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Lagarde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Damien%22%2C%22lastName%22%3A%22Plassard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gaelle%22%2C%22lastName%22%3A%22Pierron%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Daudigeos%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Lecluse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Droin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Beat%20C.%22%2C%22lastName%22%3A%22Bornhauser%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laurence%20C.%22%2C%22lastName%22%3A%22Cheung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20D.%22%2C%22lastName%22%3A%22Crispino%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Gaudry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%20A.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elizabeth%22%2C%22lastName%22%3A%22Macintyre%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carole%22%2C%22lastName%22%3A%22Barin%20Bonnigal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rishi%20S.%22%2C%22lastName%22%3A%22Kotecha%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Birgit%22%2C%22lastName%22%3A%22Geoerger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Ballerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Pierre%22%2C%22lastName%22%3A%22Bourquin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Mercher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Malinge%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Children%20with%20Down%20syndrome%20%28constitutive%20trisomy%2021%29%20that%20develop%20acute%20lymphoblastic%20leukemia%20%28DS-ALL%29%20have%20a%203-fold%20increased%20likelihood%20of%20treatment-related%20mortality%20coupled%20with%20a%20higher%20cumulative%20incidence%20of%20relapse%2C%20compared%20with%20other%20children%20with%20B-cell%20acute%20lymphoblastic%20leukemia%20%28B-ALL%29.%20This%20highlights%20the%20lack%20of%20suitable%20treatment%20for%20Down%20syndrome%20children%20with%20B-ALL.%5CnEXPERIMENTAL%20DESIGN%3A%20To%20facilitate%20the%20translation%20of%20new%20therapeutic%20agents%20into%20clinical%20trials%2C%20we%20built%20the%20first%20preclinical%20cohort%20of%20patient-derived%20xenograft%20%28PDX%29%20models%20of%20DS-ALL%2C%20comprehensively%20characterized%20at%20the%20genetic%20and%20transcriptomic%20levels%2C%20and%20have%20proven%20its%20suitability%20for%20preclinical%20studies%20by%20assessing%20the%20efficacy%20of%20drug%20combination%20between%20the%20MEK%20inhibitor%20trametinib%20and%20conventional%20chemotherapy%20agents.%5CnRESULTS%3A%20Whole-exome%20and%20RNA-sequencing%20experiments%20revealed%20a%20high%20incidence%20of%20somatic%20alterations%20leading%20to%20RAS%5C%2FMAPK%20pathway%20activation%20in%20our%20cohort%20of%20DS-ALL%2C%20as%20well%20as%20in%20other%20pediatric%20B-ALL%20presenting%20somatic%20gain%20of%20the%20chromosome%2021%20%28B-ALL%2B21%29.%20In%20murine%20and%20human%20B-cell%20precursors%2C%20activated%20KRASG12D%20functionally%20cooperates%20with%20trisomy%2021%20to%20deregulate%20transcriptional%20networks%20that%20promote%20increased%20proliferation%20and%20self%20renewal%2C%20as%20well%20as%20B-cell%20differentiation%20blockade.%20Moreover%2C%20we%20revealed%20that%20inhibition%20of%20RAS%5C%2FMAPK%20pathway%20activation%20using%20the%20MEK1%5C%2F2%20inhibitor%20trametinib%20decreased%20leukemia%20burden%20in%20several%20PDX%20models%20of%20B-ALL%2B21%2C%20and%20enhanced%20survival%20of%20DS-ALL%20PDX%20in%20combination%20with%20conventional%20chemotherapy%20agents%20such%20as%20vincristine.%5CnCONCLUSIONS%3A%20Altogether%2C%20using%20novel%20and%20suitable%20PDX%20models%2C%20this%20study%20indicates%20that%20RAS%5C%2FMAPK%20pathway%20inhibition%20represents%20a%20promising%20strategy%20to%20improve%20the%20outcome%20of%20Down%20syndrome%20children%20with%20B-cell%20precursor%20leukemia.%22%2C%22date%22%3A%22Jul%2001%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F1078-0432.CCR-19-3519%22%2C%22ISSN%22%3A%221078-0432%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A32Z%22%7D%7D%2C%7B%22key%22%3A%22FYUEJG2F%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Gerby%20and%20Hoang%22%2C%22parsedDate%22%3A%222020-05-07%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EGerby%2C%20Bastien%2C%20and%20Trang%20Hoang.%20%26%23x201C%3BA%20Targetable%20Cue%20in%20T-Cell%20Malignancy.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20135%2C%20no.%2019%20%28May%207%2C%202020%29%3A%201616%26%23x2013%3B17.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020005142%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood.2020005142%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22A%20targetable%20cue%20in%20T-cell%20malignancy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Gerby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Trang%22%2C%22lastName%22%3A%22Hoang%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222020-05-7%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood.2020005142%22%2C%22ISSN%22%3A%220006-4971%2C%201528-0020%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fashpublications.org%5C%2Fblood%5C%2Farticle%5C%2F135%5C%2F19%5C%2F1616%5C%2F454726%5C%2FA-targetable-cue-in-Tcell-malignancy%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A39Z%22%7D%7D%2C%7B%22key%22%3A%22NXH5WW5V%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Vergez%20et%20al.%22%2C%22parsedDate%22%3A%222020-05-06%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EVergez%2C%20Fran%26%23xE7%3Bois%2C%20Marie-Laure%20Nicolau-Travers%2C%20Sarah%20Bertoli%2C%20Jean-Baptiste%20Rieu%2C%20Suzanne%20Tavitian%2C%20Pierre%20Bories%2C%20Isabelle%20Luquet%2C%20et%20al.%20%26%23x201C%3BCD34%2BCD38%26%23x2212%3BCD123%2B%20Leukemic%20Stem%20Cell%20Frequency%20Predicts%20Outcome%20in%20Older%20Acute%20Myeloid%20Leukemia%20Patients%20Treated%20by%20Intensive%20Chemotherapy%20but%20Not%20Hypomethylating%20Agents.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%205%20%28May%206%2C%202020%29%3A%201174.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12051174%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12051174%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22CD34%2BCD38%5Cu2212CD123%2B%20Leukemic%20Stem%20Cell%20Frequency%20Predicts%20Outcome%20in%20Older%20Acute%20Myeloid%20Leukemia%20Patients%20Treated%20by%20Intensive%20Chemotherapy%20but%20Not%20Hypomethylating%20Agents%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Nicolau-Travers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22The%20prognostic%20impact%20of%20immunophenotypic%20CD34%2BCD38%5Cu2212CD123%2B%20leukemic%20stem%20cell%20%28iLSC%29%20frequency%20at%20diagnosis%20has%20been%20demonstrated%20in%20younger%20patients%20treated%20by%20intensive%20chemotherapy%2C%20however%2C%20this%20is%20less%20clear%20in%20older%20patients.%20Furthermore%2C%20the%20impact%20of%20iLSC%20in%20patients%20treated%20by%20hypomethylating%20agents%20is%20unknown.%20In%20this%20single-center%20study%2C%20we%20prospectively%20assessed%20the%20CD34%2BCD38%5Cu2212CD123%2B%20iLSC%20frequency%20at%20diagnosis%20in%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20aged%2060%20years%20or%20older.%20In%20a%20cohort%20of%20444%20patients%2C%20the%20median%20percentage%20of%20iLSC%20at%20diagnosis%20was%204.3%25.%20Significant%20differences%20were%20found%20between%20treatment%20groups%20with%20a%20lower%20median%20in%20the%20intensive%20chemotherapy%20group%20%280.6%25%29%20compared%20to%20hypomethylating%20agents%20%288.0%25%29%20or%20supportive%20care%20%2811.1%25%29%20%28p%20%3C0.0001%29.%20In%20the%20intensive%20chemotherapy%20group%2C%20the%20median%20overall%20survival%20was%2034.5%20months%20in%20patients%20with%20iLSC%20%5Cu22640.10%25%20and%2014.6%20months%20in%20patients%20with%20%3E0.10%25%20%28p%20%3D%200.031%29.%20In%20the%20multivariate%20analyses%20of%20this%20group%2C%20iLSC%20frequency%20was%20significantly%20and%20independently%20associated%20with%20the%20incidence%20of%20relapse%2C%20event-free%2C%20relapse-free%2C%20and%20overall%20survival.%20However%2C%20iLSC%20frequency%20had%20no%20prognostic%20impact%20on%20patients%20treated%20by%20hypomethylating%20agents.%20Thus%2C%20the%20iLSC%20frequency%20at%20diagnosis%20is%20an%20independent%20prognostic%20factor%20in%20older%20acute%20myeloid%20patients%20treated%20by%20intensive%20chemotherapy%20but%20not%20hypomethylating%20agents.%22%2C%22date%22%3A%222020-05-06%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12051174%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F5%5C%2F1174%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A24Z%22%7D%7D%2C%7B%22key%22%3A%223UT74ZQI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bertoli%20et%20al.%22%2C%22parsedDate%22%3A%222020-03-25%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBertoli%2C%20Sarah%2C%20Pierre-Yves%20Dumas%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Laetitia%20Largeaud%2C%20Audrey%20Bidet%2C%20Eric%20Delabesse%2C%20Suzanne%20Tavitian%2C%20et%20al.%20%26%23x201C%3BOutcome%20of%20Relapsed%20or%20Refractory%20FLT3-Mutated%20Acute%20Myeloid%20Leukemia%20before%20Second-Generation%20FLT3%20Tyrosine%20Kinase%20Inhibitors%3A%20A%20Toulouse%26%23x2013%3BBordeaux%20DATAML%20Registry%20Study.%26%23x201D%3B%20%3Ci%3ECancers%3C%5C%2Fi%3E%2012%2C%20no.%204%20%28March%2025%2C%202020%29%3A%20773.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12040773%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3390%5C%2Fcancers12040773%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcome%20of%20Relapsed%20or%20Refractory%20FLT3-Mutated%20Acute%20Myeloid%20Leukemia%20before%20Second-Generation%20FLT3%20Tyrosine%20Kinase%20Inhibitors%3A%20A%20Toulouse%5Cu2013Bordeaux%20DATAML%20Registry%20Study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre-Yves%22%2C%22lastName%22%3A%22Dumas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Bidet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Gadaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harmony%22%2C%22lastName%22%3A%22Leroy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Philippe%22%2C%22lastName%22%3A%22Vial%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Lechevalier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22Klein%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anne-Charlotte%22%2C%22lastName%22%3A%22De%20Grande%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Pigneux%22%7D%5D%2C%22abstractNote%22%3A%22A%20recent%20phase%203%20trial%20showed%20that%20the%20outcome%20of%20patients%20with%20relapsed%5C%2Frefractory%20%28R%5C%2FR%29%20FLT3-mutated%20acute%20myeloid%20leukemia%20%28AML%29%20improved%20with%20gilteritinib%2C%20a%20single-agent%20second-generation%20FLT3%20tyrosine%20kinase%20inhibitor%20%28TKI%29%2C%20compared%20with%20standard%20of%20care.%20In%20this%20trial%2C%20the%20response%20rate%20with%20standard%20therapy%20was%20particularly%20low.%20We%20retrospectively%20assessed%20the%20characteristics%20and%20outcome%20of%20patients%20with%20R%5C%2FR%20FLT3-mutated%20AML%20included%20in%20the%20Toulouse%5Cu2013Bordeaux%20DATAML%20registry.%20Among%20347%20patients%20who%20received%20FLT3%20TKI-free%20intensive%20chemotherapy%20as%20first-line%20treatment%2C%20174%20patients%20were%20refractory%20%28n%20%3D%2048%2C%2027.6%25%29%20or%20relapsed%20%28n%20%3D%20126%2C%2072.4%25%29.%20Salvage%20treatments%20consisted%20of%20intensive%20chemotherapy%20%28n%20%3D%2099%2C%2056.9%25%29%2C%20azacitidine%20or%20low-dose%20cytarabine%20%28n%20%3D%209%2C%205.1%25%29%2C%20other%20low-intensity%20treatments%20%28n%20%3D%2017%2C%209.8%25%29%2C%20immediate%20allogeneic%20stem%20cell%20transplantation%20%28n%20%3D%204%2C%202.3%25%29%20or%20best%20supportive%20care%20only%20%28n%20%3D%2045%2C%2025.9%25%29.%20Among%20the%20114%20patients%20who%20previously%20received%20FLT3%20TKI-free%20intensive%20chemotherapy%20as%20first-line%20treatment%20%28refractory%2C%20n%20%3D%2032%2C%2028.1%25%3B%20relapsed%2C%20n%20%3D%2082%2C%2071.9%25%29%2C%20the%20rate%20of%20CR%20%28complete%20remission%29%20or%20CRi%20%28complete%20remission%20with%20incomplete%20hematologic%20recovery%29%20after%20high-%20or%20low-intensity%20salvage%20treatment%20was%2050.0%25%2C%20with%20a%20bridge%20to%20transplant%20in%2034.2%25%20%28n%20%3D%2039%29%20of%20cases.%20The%20median%20overall%20survival%20%28OS%29%20was%208.2%20months%20%28interquartile%20range%2C%203.0%5Cu201332%29%3B%201-%2C%203-%20and%205-year%20OS%20rates%20were%2036.0%25%20%2895%25CI%3A%2027%5Cu201345%29%2C%2024.7%25%20%2895%25CI%3A%201%5Cu201333%29%20and%2019.7%25%20%2895%25CI%3A%201%5Cu201328%29%2C%20respectively.%20In%20this%20real-word%20study%2C%20although%20response%20rate%20appeared%20higher%20than%20the%20controlled%20arm%20of%20the%20ADMIRAL%20trial%2C%20the%20outcome%20of%20patients%20with%20R%5C%2FR%20FLT3-mutated%20AML%20remains%20very%20poor%20with%20standard%20salvage%20therapy.%22%2C%22date%22%3A%222020-03-25%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.3390%5C%2Fcancers12040773%22%2C%22ISSN%22%3A%222072-6694%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.mdpi.com%5C%2F2072-6694%5C%2F12%5C%2F4%5C%2F773%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A30Z%22%7D%7D%2C%7B%22key%22%3A%22UNKB63LF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bertoli%20et%20al.%22%2C%22parsedDate%22%3A%222020-02-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBertoli%2C%20Sarah%2C%20Suzanne%20Tavitian%2C%20Emilie%20B%26%23xE9%3Brard%2C%20V%26%23xE9%3Bronique%20Mansat-De%20Mas%2C%20Laetitia%20Largeaud%2C%20No%26%23xE9%3Bmie%20Gadaud%2C%20Jean-Baptiste%20Rieu%2C%20et%20al.%20%26%23x201C%3BMore%20than%20Ten%20Percent%20of%20Relapses%20Occur%20after%20Five%20Years%20in%20AML%20Patients%20with%20NPM1%20Mutation.%26%23x201D%3B%20%3Ci%3ELeukemia%20%26amp%3B%20Lymphoma%3C%5C%2Fi%3E%2C%20February%205%2C%202020%2C%201%26%23x2013%3B4.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2019.1706733%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2019.1706733%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22More%20than%20ten%20percent%20of%20relapses%20occur%20after%20five%20years%20in%20AML%20patients%20with%20NPM1%20mutation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Mansat-De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Gadaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Feb%2005%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F10428194.2019.1706733%22%2C%22ISSN%22%3A%221029-2403%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A09Z%22%7D%7D%2C%7B%22key%22%3A%228B4VME9N%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Beziat%20et%20al.%22%2C%22parsedDate%22%3A%222020%22%2C%22numChildren%22%3A0%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBeziat%2C%20Guillaume%2C%20Suzanne%20Tavitian%2C%20Sarah%20Bertoli%2C%20Fran%26%23xE7%3Boise%20Huguet%2C%20Laetitia%20Largeaud%2C%20Isabelle%20Luquet%2C%20Fran%26%23xE7%3Bois%20Vergez%2C%20et%20al.%20%26%23x201C%3BDactinomycin%20in%20Acute%20Myeloid%20Leukemia%20with%20NPM1%20Mutations.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Haematology%3C%5C%2Fi%3E%20105%2C%20no.%203%20%282020%29%3A%20302%26%23x2013%3B7.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13438%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13438%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Dactinomycin%20in%20acute%20myeloid%20leukemia%20with%20NPM1%20mutations%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guillaume%22%2C%22lastName%22%3A%22Beziat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%5Cu2010Baptiste%22%2C%22lastName%22%3A%22Rieu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2209%5C%2F2020%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fejh.13438%22%2C%22ISSN%22%3A%220902-4441%2C%201600-0609%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fejh.13438%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-06-14T14%3A21%3A22Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Bories, Pierre, Naïs Prade, Stéphanie Lagarde, Bastien Cabarrou, Laetitia Largeaud, Julien Plenecassagnes, Isabelle Luquet, et al. “Impact of TP53 Mutations in Acute Myeloid Leukemia Patients Treated with Azacitidine.” Edited by Francesco Bertolini. PLOS ONE<\/i> 15, no. 10 (October 1, 2020): e0238795. https:\/\/doi.org\/10.1371\/journal.pone.0238795<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dumas, Pierre-Yves, Sarah Bertoli, Emilie Bérard, Thibaut Leguay, Suzanne Tavitian, Jean Galtier, Camille Alric, et al. “Delivering HDAC over 3 or 5 Days as Consolidation in AML Impacts Health Care Resource Consumption but Not Outcome.” Blood Advances<\/i> 4, no. 16 (August 25, 2020): 3840–49. https:\/\/doi.org\/10.1182\/bloodadvances.2020002511<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Fagnan, Alexandre, Frederik Otzen Bagger, Maria-Riera Piqué-Borràs, Cathy Ignacimouttou, Alexis Caulier, Cécile K. Lopez, Elie Robert, et al. “Human Erythroleukemia Genetics and Transcriptomes Identify Master Transcription Factors as Functional Disease Drivers.” Blood<\/i> 136, no. 6 (August 6, 2020): 698–714. https:\/\/doi.org\/10.1182\/blood.2019003062<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Rohmer, Julien, Amélie Couteau‐Chardon, Julie Trichereau, Kewin Panel, Cyrielle Gesquiere, Raouf Ben Abdelali, Audrey Bidet, et al. “Epidemiology, Clinical Picture and Long‐term Outcomes of FIP1L1‐PDGFRA‐positive Myeloid Neoplasm with Eosinophilia: Data from 151 Patients.” American Journal of Hematology<\/i>, July 28, 2020, ajh.25945. https:\/\/doi.org\/10.1002\/ajh.25945<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Dumas, Pierre-Yves, Sarah Bertoli, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Thibaut Leguay, et al. “Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study.” Cancers<\/i> 12, no. 8 (July 24, 2020): 2044. https:\/\/doi.org\/10.3390\/cancers12082044<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Laurent, Anouchka P., Aurélie Siret, Cathy Ignacimouttou, Kunjal Panchal, M’Boyba Diop, Silvia Jenni, Yi-Chien Tsai, et al. “Constitutive Activation of RAS\/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia.” Clinical Cancer Research: An Official Journal of the American Association for Cancer Research<\/i> 26, no. 13 (July 1, 2020): 3307–18. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-3519<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Gerby, Bastien, and Trang Hoang. “A Targetable Cue in T-Cell Malignancy.” Blood<\/i> 135, no. 19 (May 7, 2020): 1616–17. https:\/\/doi.org\/10.1182\/blood.2020005142<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Vergez, François, Marie-Laure Nicolau-Travers, Sarah Bertoli, Jean-Baptiste Rieu, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, et al. “CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents.” Cancers<\/i> 12, no. 5 (May 6, 2020): 1174. https:\/\/doi.org\/10.3390\/cancers12051174<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bertoli, Sarah, Pierre-Yves Dumas, Emilie Bérard, Laetitia Largeaud, Audrey Bidet, Eric Delabesse, Suzanne Tavitian, et al. “Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study.” Cancers<\/i> 12, no. 4 (March 25, 2020): 773. https:\/\/doi.org\/10.3390\/cancers12040773<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bertoli, Sarah, Suzanne Tavitian, Emilie Bérard, Véronique Mansat-De Mas, Laetitia Largeaud, Noémie Gadaud, Jean-Baptiste Rieu, et al. “More than Ten Percent of Relapses Occur after Five Years in AML Patients with NPM1 Mutation.” Leukemia & Lymphoma<\/i>, February 5, 2020, 1–4. https:\/\/doi.org\/10.1080\/10428194.2019.1706733<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Beziat, Guillaume, Suzanne Tavitian, Sarah Bertoli, Françoise Huguet, Laetitia Largeaud, Isabelle Luquet, François Vergez, et al. “Dactinomycin in Acute Myeloid Leukemia with NPM1 Mutations.” European Journal of Haematology<\/i> 105, no. 3 (2020): 302–7. https:\/\/doi.org\/10.1111\/ejh.13438<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][et_pb_toggle title=”PUBLICATIONS 2019″ open_toggle_text_color=”#5EC7ED” open_toggle_background_color=”#ffffff” closed_toggle_text_color=”#505659″ closed_toggle_background_color=”#AEE3F6″ icon_color=”#505659″ open_icon_color=”#505659″ _builder_version=”4.16″ _module_preset=”default” title_text_color=”#505659″ title_font=”|600||on|||||” title_text_align=”center” title_font_size=”22px” closed_title_text_align=”center” closed_title_font_size=”22px” body_text_align=”left” body_text_color=”#505659″ body_font_size=”16px” text_orientation=”center” global_colors_info=”{}”]<\/p>\n

\n\n\t\t7813506<\/span>\n\t\t<\/span>\n\t\t9RREECEZ<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t2019<\/span>\n <\/span>\n items<\/span>\n\t\t1<\/span>\n\t\tchicago-fullnote-bibliography<\/span>\n\t\t0<\/span>\n\t\tdate<\/span>\n\t\tdesc<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n\t\t<\/span>\n <\/span>\n 40076<\/span>\n\t\thttps:\/\/www.crct-inserm.fr\/wp-content\/plugins\/zotpress\/<\/span>\n\n\t\t
\n\t\t\t
\n\t\t\t\t%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3A%22zotpress-d139118678b5a7e97cb8b9d470a67a28%22%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22XZPZPTJ6%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22P%5Cu00e9ricart%20et%20al.%22%2C%22parsedDate%22%3A%222019-12-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EP%26%23xE9%3Bricart%2C%20Sarah%2C%20Charlotte%20Waysse%2C%20Aurore%20Siegfried%2C%20Stephanie%20Struski%2C%20Eric%20Delabesse%2C%20Camille%20Laurent%2C%20and%20Sol%26%23xE8%3Bne%20Evrard.%20%26%23x201C%3BSubsequent%20Development%20of%20Histiocytic%20Sarcoma%20and%20Follicular%20Lymphoma%3A%20Cytogenetics%20and%20next-Generation%20Sequencing%20Analyses%20Provide%20Evidence%20for%20Transdifferentiation%20of%20Early%20Common%20Lymphoid%20Precursor-a%20Case%20Report%20and%20Review%20of%20Literature.%26%23x201D%3B%20%3Ci%3EVirchows%20Archiv%3A%20An%20International%20Journal%20of%20Pathology%3C%5C%2Fi%3E%2C%20December%205%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-019-02691-w%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00428-019-02691-w%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Subsequent%20development%20of%20histiocytic%20sarcoma%20and%20follicular%20lymphoma%3A%20cytogenetics%20and%20next-generation%20sequencing%20analyses%20provide%20evidence%20for%20transdifferentiation%20of%20early%20common%20lymphoid%20precursor-a%20case%20report%20and%20review%20of%20literature%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22P%5Cu00e9ricart%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Charlotte%22%2C%22lastName%22%3A%22Waysse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aurore%22%2C%22lastName%22%3A%22Siegfried%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephanie%22%2C%22lastName%22%3A%22Struski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sol%5Cu00e8ne%22%2C%22lastName%22%3A%22Evrard%22%7D%5D%2C%22abstractNote%22%3A%22Histiocytic%20sarcoma%20%28HS%29%20is%20a%20rare%20aggressive%20hematologic%20neoplasm%20that%20can%20be%20associated%20with%20low-grade%20B%20cell%20lymphoma.%20The%20development%20of%20both%20neoplasms%20is%20currently%20being%20considered%20a%20transdifferentiation%20mechanism%20but%20remains%20elusive.%20We%20report%20the%20case%20of%20a%2065-year-old%20patient%20with%20synchronous%20development%20of%20peritoneal%5C%2Fabdominal%20HS%20and%20grade%201-2%20follicular%20lymphoma%20%28FL%29.%20Cytogenetic%20analysis%20and%20targeted%20next-generation%20sequencing%20of%20both%20FL%20and%20HS%20tumors%20identified%20common%20genomic%20alterations%20such%20as%20IGH-BCL2%20rearrangement%2C%20CREBBP%20and%20KMT2D%2C%20and%20aberrations%20of%20chromosomes%209q%20and%2019q.%20However%2C%20only%20the%20HS%20tumor%20had%20a%20KRAS%20mutation%20while%20the%20lymph%20node%20involved%20by%20FL%20harbored%20a%20TNFAIP3%20mutation%20and%20both%20tumors%20also%20showed%20distinct%20chromosomal%20alterations.%20This%20report%20strengthens%20the%20hypothesis%20of%20a%20common%20lymphoid%20progenitor%20which%20accumulates%20genetic%20alterations%20leading%20to%20two%20different%20hematologic%20malignant%20diseases%20with%20significantly%20distinct%20prognoses.%22%2C%22date%22%3A%22Dec%2005%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00428-019-02691-w%22%2C%22ISSN%22%3A%221432-2307%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22QS3I9WIA%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A49Z%22%7D%7D%2C%7B%22key%22%3A%22VMPXI2HY%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Lopez%20et%20al.%22%2C%22parsedDate%22%3A%222019-10-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELopez%2C%20Cecile%20K.%2C%20Esteve%20Noguera%2C%20Vaia%20Stavropoulou%2C%20Elie%20Robert%2C%20Zakia%20Aid%2C%20Paola%20Ballerini%2C%20Chrystele%20Bilhou-Nabera%2C%20et%20al.%20%26%23x201C%3BOntogenic%20Changes%20in%20Hematopoietic%20Hierarchy%20Determine%20Pediatric%20Specificity%20and%20Disease%20Phenotype%20in%20Fusion%20Oncogene-Driven%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3ECancer%20Discovery%3C%5C%2Fi%3E%2C%20October%2029%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2159-8290.CD-18-1463%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1158%5C%2F2159-8290.CD-18-1463%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ontogenic%20changes%20in%20hematopoietic%20hierarchy%20determine%20pediatric%20specificity%20and%20disease%20phenotype%20in%20fusion%20oncogene-driven%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecile%20K.%22%2C%22lastName%22%3A%22Lopez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Esteve%22%2C%22lastName%22%3A%22Noguera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vaia%22%2C%22lastName%22%3A%22Stavropoulou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elie%22%2C%22lastName%22%3A%22Robert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zakia%22%2C%22lastName%22%3A%22Aid%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paola%22%2C%22lastName%22%3A%22Ballerini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chrystele%22%2C%22lastName%22%3A%22Bilhou-Nabera%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Helene%22%2C%22lastName%22%3A%22Lapillonne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Boudia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cecile%22%2C%22lastName%22%3A%22Thirant%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexandre%22%2C%22lastName%22%3A%22Fagnan%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Laure%22%2C%22lastName%22%3A%22Arcangeli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%20J.%22%2C%22lastName%22%3A%22Kinston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22M%27boyba%22%2C%22lastName%22%3A%22Diop%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bastien%22%2C%22lastName%22%3A%22Job%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yann%22%2C%22lastName%22%3A%22Lecluse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Erika%22%2C%22lastName%22%3A%22Brunet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Loelia%22%2C%22lastName%22%3A%22Babin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Luc%22%2C%22lastName%22%3A%22Villeval%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%20H.%20F.%20M.%22%2C%22lastName%22%3A%22Peters%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22William%22%2C%22lastName%22%3A%22Vainchenker%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Muriel%22%2C%22lastName%22%3A%22Gaudry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Riccardo%22%2C%22lastName%22%3A%22Masetti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Franco%22%2C%22lastName%22%3A%22Locatelli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sebastien%22%2C%22lastName%22%3A%22Malinge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claus%22%2C%22lastName%22%3A%22Nerlov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Droin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Camille%22%2C%22lastName%22%3A%22Lobry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Godin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Olivier%20A.%22%2C%22lastName%22%3A%22Bernard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Berthold%22%2C%22lastName%22%3A%22Gottgens%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arnaud%22%2C%22lastName%22%3A%22Petit%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francoise%22%2C%22lastName%22%3A%22Pflumio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juerg%22%2C%22lastName%22%3A%22Schwaller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Mercher%22%7D%5D%2C%22abstractNote%22%3A%22Fusion%20oncogenes%20are%20prevalent%20in%20several%20pediatric%20cancers%2C%20yet%20little%20is%20known%20about%20the%20specific%20associations%20between%20age%20and%20phenotype.%20We%20observed%20that%20fusion%20oncogenes%2C%20like%20ETO2-GLIS2%2C%20are%20associated%20with%20acute%20megakaryoblastic%20or%20other%20myeloid%20leukemia%20subtypes%20in%20an%20age-dependent%20manner.%20Analysis%20of%20a%20novel%20inducible%20transgenic%20mouse%20model%20showed%20that%20ETO2-GLIS2%20expression%20in%20fetal%20hematopoietic%20stem%20cells%20induced%20rapid%20megakaryoblastic%20leukemia%20while%20expression%20in%20adult%20bone%20marrow%20hematopoietic%20stem%20cells%20resulted%20in%20a%20shift%20toward%20myeloid%20transformation%20with%20a%20strikingly%20delayed%20in%20vivo%20leukemogenic%20potential.%20Chromatin%20accessibility%20and%20single%20cell%20transcriptome%20analyses%20indicate%20ontogeny-dependent%20intrinsic%20and%20ETO2-GLIS2-induced%20differences%20in%20key%20transcription%20factor%20activities%2C%20including%20ERG%2C%20SPI1%2C%20GATA1%20and%20CEBPA.%20Importantly%2C%20switching%20off%20the%20fusion%20oncogene%20restored%20terminal%20differentiation%20of%20the%20leukemic%20blasts.%20Together%2C%20these%20data%20show%20that%20aggressiveness%20and%20phenotypes%20in%20pediatric%20acute%20myeloid%20leukemia%20result%20from%20an%20ontogeny-related%20differential%20susceptibility%20to%20transformation%20by%20fusion%20oncogenes.%22%2C%22date%22%3A%22Oct%2029%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1158%5C%2F2159-8290.CD-18-1463%22%2C%22ISSN%22%3A%222159-8290%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22LMI7WIKW%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Largeaud%20et%20al.%22%2C%22parsedDate%22%3A%222019-09-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELargeaud%2C%20Laetitia%2C%20Sarah%20Bertoli%2C%20Emilie%20B%26%23xE9%3Brard%2C%20St%26%23xE9%3Bphanie%20Dufrechou%2C%20Na%26%23xEF%3Bs%20Prade%2C%20No%26%23xE9%3Bmie%20Gadaud%2C%20Suzanne%20Tavitian%2C%20et%20al.%20%26%23x201C%3BOutcome%20of%20Relapsed%5C%2FRefractory%20AML%20Patients%20with%20IDH1R132%20Mutations%20in%20Real%20Life%20before%20the%20Era%20of%20IDH1%20Inhibitors.%26%23x201D%3B%20%3Ci%3ELeukemia%20%26amp%3B%20Lymphoma%3C%5C%2Fi%3E%2C%20September%2030%2C%202019%2C%201%26%23x2013%3B4.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2019.1668937%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1080%5C%2F10428194.2019.1668937%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcome%20of%20relapsed%5C%2Frefractory%20AML%20patients%20with%20IDH1R132%20mutations%20in%20real%20life%20before%20the%20era%20of%20IDH1%20inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Gadaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%20De%22%2C%22lastName%22%3A%22Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Sep%2030%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1080%5C%2F10428194.2019.1668937%22%2C%22ISSN%22%3A%221029-2403%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A37Z%22%7D%7D%2C%7B%22key%22%3A%22Y77L9KFV%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bertoli%20et%20al.%22%2C%22parsedDate%22%3A%222019-06-07%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBertoli%2C%20Sarah%2C%20Suzanne%20Tavitian%2C%20Pierre%20Bories%2C%20Isabelle%20Luquet%2C%20Eric%20Delabesse%2C%20Thibault%20Comont%2C%20Audrey%20Sarry%2C%20Fran%26%23xE7%3Boise%20Huguet%2C%20Emilie%20B%26%23xE9%3Brard%2C%20and%20Christian%20R%26%23xE9%3Bcher.%20%26%23x201C%3BOutcome%20of%20Patients%20Aged%2060-75%26%23xA0%3BYears%20with%20Newly%20Diagnosed%20Secondary%20Acute%20Myeloid%20Leukemia%3A%20A%20Single-Institution%20Experience.%26%23x201D%3B%20%3Ci%3ECancer%20Medicine%3C%5C%2Fi%3E%2C%20June%207%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.2020%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fcam4.2020%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcome%20of%20patients%20aged%2060-75%5Cu00a0years%20with%20newly%20diagnosed%20secondary%20acute%20myeloid%20leukemia%3A%20A%20single-institution%20experience%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibault%22%2C%22lastName%22%3A%22Comont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22A%20recent%20phase%203%20trial%20showed%20that%20outcome%20of%20older%20patients%20with%20secondary%20acute%20myeloid%20leukemia%20%28AML%29%20may%20be%20improved%20by%20a%20liposomal%20encapsulation%20of%20cytarabine%20and%20daunorubicin%20%28CPX-351%29.%20This%20phase%203%20study%20represents%20a%20unique%20example%20of%20prospective%20data%20in%20this%20rare%20subgroup%20providing%20basis%20for%20comparison%20with%20real%20life%20data.%20Here%2C%20we%20retrospectively%20assessed%20characteristics%20and%20outcome%20of%20patients%20aged%2060-75%5Cu00a0years%20with%20secondary%20or%20therapy-related%20AML%20in%20real%20life.%20Out%20of%20218%20patients%20that%20fulfilled%20CPX-351%20study%20criteria%2C%20181%20patients%20%2883.0%25%29%20received%20antileukemic%20treatment%20either%20intensive%20chemotherapy%20%28n%5Cu00a0%3D%5Cu00a0121%29%20or%20hypomethylating%20agents%20%28HMA%2C%20n%5Cu00a0%3D%5Cu00a060%29.%20As%20compared%20with%20patients%20treated%20by%20chemotherapy%2C%20HMA-treated%20patients%20were%20older%2C%20had%20lower%20WBC%2C%20more%20often%20AML%20with%20antecedent%20myelodysplastic%20syndrome%20and%20adverse%20cytogenetic%20risk.%20In%20chemotherapy-treated%20patients%2C%20the%20complete%20response%20rate%20was%2069%25%2C%20median%20overall%20survival%20%28OS%29%20was%2011%5Cu00a0months%20whereas%203-year%20and%205-year%20OS%20was%2021%25%20and%2017%25%2C%20respectively.%20In%20HMA-treated%20patients%2C%20the%20complete%20response%20rate%20was%2015%25%2C%20median%20OS%20was%2011%5Cu00a0months%20whereas%203-year%20and%205-year%20OS%20was%2015%25%20and%202%25%2C%20respectively.%20In%20conclusion%2C%20although%20outcome%20of%20older%20patients%20with%20high-risk%20AML%20is%20very%20poor%2C%20a%20significant%20proportion%20of%20patients%20treated%20by%20standard%20intensive%20chemotherapy%20but%20not%20HMA%20are%20long-term%20survivors.%22%2C%22date%22%3A%22Jun%2007%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fcam4.2020%22%2C%22ISSN%22%3A%222045-7634%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A20Z%22%7D%7D%2C%7B%22key%22%3A%2287FF4FJI%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Comont%20et%20al.%22%2C%22parsedDate%22%3A%222019-05-01%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EComont%2C%20T.%2C%20K.%20Delavigne%2C%20P.%20Cougoul%2C%20S.%20Bertoli%2C%20E.%20Delabesse%2C%20P.%20Fenaux%2C%20and%20O.%20Beyne-Rauzy.%20%26%23x201C%3B%5BManagement%20of%20myelodysplastic%20syndromes%20in%202019%3A%20An%20update%5D.%26%23x201D%3B%20%3Ci%3ELa%20Revue%20De%20Medecine%20Interne%3C%5C%2Fi%3E%2C%20May%201%2C%202019.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.revmed.2019.04.001%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.revmed.2019.04.001%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22%5BManagement%20of%20myelodysplastic%20syndromes%20in%202019%3A%20An%20update%5D%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22T.%22%2C%22lastName%22%3A%22Comont%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22K.%22%2C%22lastName%22%3A%22Delavigne%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Cougoul%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22S.%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22E.%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22P.%22%2C%22lastName%22%3A%22Fenaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22O.%22%2C%22lastName%22%3A%22Beyne-Rauzy%22%7D%5D%2C%22abstractNote%22%3A%22Myelodysplastic%20syndromes%20are%20a%20heterogeneous%20group%20of%20clonal%20myeloid%20disorders%20characterized%20by%20peripheral%20cytopenias%20and%20an%20increased%20risk%20of%20progression%20to%20acute%20myeloid%20leukemia.%20Inflammatory%2C%20auto-immune%20or%20syndromic%20symptoms%20can%20make%20the%20diagnosis%20difficult.%20Diagnosis%20is%20currently%20based%20on%20bone%20marrow%20cytology%20but%20cytogenetics%20and%20molecular%20features%20are%20currently%20overpassing%20their%20initial%20prognostic%20function%20%28allowing%20early%20diagnosis%20and%20prediction%20of%20therapeutic%20response%29.%20The%20prognostic%20classification%20is%20based%20on%20the%20Revised%20International%20Prognostic%20Scoring%20System%2C%20which%20also%20provides%20guidance%20for%20therapeutic%20management.%20The%20treatment%20of%20low-risk%20myelodysplastic%20syndromes%20is%20based%20on%20the%20correction%20of%20cytopenias%20%28erythropoiesis%20stimulating%20agents%2C%20transfusions%2C%20lenalidomide%2C%20etc.%29%2C%20whereas%20in%20high-risk%20group%2C%20the%20goal%20is%20the%20control%20of%20the%20leukemic%20clone%20%28hypomethylating%20agents%2C%20allograft%20of%20hematopoietic%20stem%20cell%20transplantation%29.%20Other%20molecules%20are%20used%20to%20manage%20complications%20of%20cytopenias%20or%20transfusion%20%28anti-infectious%20prophylaxis%20and%20treatments%2C%20martial%20chelation%29.%20New%20molecules%20are%20being%20studied%20with%20some%20interesting%20results%20%28luspatercept%2C%20venetoclax%29.%20This%20article%20aims%20to%20provide%20an%20update%20on%20the%20knowledge%20that%20an%20internist%20should%20know%20for%20the%20practical%20management%20of%20myelodysplastic%20syndromes%20in%202019.%22%2C%22date%22%3A%22May%2001%2C%202019%22%2C%22language%22%3A%22fre%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.revmed.2019.04.001%22%2C%22ISSN%22%3A%221768-3122%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22LNNP3XDQ%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Largeaud%20et%20al.%22%2C%22parsedDate%22%3A%222019-04-27%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELargeaud%2C%20Laetitia%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Sarah%20Bertoli%2C%20St%26%23xE9%3Bphanie%20Dufrechou%2C%20Na%26%23xEF%3Bs%20Prade%2C%20No%26%23xE9%3Bmie%20Gadaud%2C%20Suzanne%20Tavitian%2C%20et%20al.%20%26%23x201C%3BOutcome%20of%20AML%20Patients%20with%20IDH2%20Mutations%20in%20Real%20World%20before%20the%20Era%20of%20IDH2%20Inhibitors.%26%23x201D%3B%20%3Ci%3ELeukemia%20Research%3C%5C%2Fi%3E%2081%20%28April%2027%2C%202019%29%3A%2082%26%23x2013%3B87.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.leukres.2019.04.010%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.leukres.2019.04.010%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Outcome%20of%20AML%20patients%20with%20IDH2%20mutations%20in%20real%20world%20before%20the%20era%20of%20IDH2%20inhibitors%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Laetitia%22%2C%22lastName%22%3A%22Largeaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22St%5Cu00e9phanie%22%2C%22lastName%22%3A%22Dufrechou%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Na%5Cu00efs%22%2C%22lastName%22%3A%22Prade%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22No%5Cu00e9mie%22%2C%22lastName%22%3A%22Gadaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Bories%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Luquet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22De%20Mas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22Describing%20the%20prognosis%20of%20sub-groups%20of%20acute%20myeloid%20leukemia%20%28AML%29%20patients%20treated%20in%20real%20world%20with%20current%20therapies%20is%20becoming%20increasingly%20relevant%20to%20estimate%20the%20benefit%20that%20new%20targeted%20drugs%20will%20bring%20in%20the%20field.%20This%20is%20particularly%20the%20case%20when%20novel%20drugs%20are%20registered%20on%20the%20basis%20of%20non-randomized%20studies.%20IDH2%20inhibitors%20have%20recently%20emerged%20as%20promising%20drugs%20in%20patients%20with%20IDH2R140%20or%20IDH2R172%20mutations.%20Enasidenib%2C%20a%20first-in-class%20IDH2%20inhibitor%2C%20has%20been%20approved%20following%20promising%20results%20of%20a%20phase%201-2%20clinical%20trial%20in%20relapsed%20or%20refractory%20AML%20patients%20with%20IDH2%20mutations.%20In%20this%20study%2C%20we%20described%20the%20characteristics%2C%20treatments%20and%20outcome%20of%2075%20IDH2%20mutated%20patients%20both%20at%20diagnosis%20and%20relapse%20or%20refractory%20disease.%20Among%20the%2033%20relapsed%5C%2Frefractory%20AML%20patients%20with%20either%20IDH2R140%20or%20IDH2R172%2C%2028%20%2884.8%25%29%20patients%20received%20salvage%20therapy%20and%2014%20achieved%20a%20complete%20response%20%2850%25%29.%20Median%20duration%20of%20response%20was%2015.2%20months.%20Median%2C%201-y%2C%203-y%20and%205-y%20OS%20were%2015.1%20months%20%28IQR%2C%204.6-37.7%29%2C%2053.1%25%20%2895%25%20CI%2C%2033.2-69.5%29%2C%2029.2%25%20%2895%25%20CI%2C%2012.6-48.1%29%20and%2024.4%25%20%2895%25%20CI%2C%209.3-43.1%29%2C%20respectively.%20In%20responding%20patients%2C%20median%20OS%20was%2037.7%20months%20and%201-y%2C%203-y%20and%205-y%20OS%20was%2085.7%25%2C%2057.1%25%20and%2047.6%25%2C%20respectively.%20In%20non-responding%20patients%2C%20median%20OS%20was%205.0%20months%20%28IQR%2C%204.5-8.6%29%20and%201-y%20and%203-y%20OS%20was%2017.9%25%20and%200%25%2C%20respectively.%20Thus%2C%20a%20substantial%20number%20of%20R%5C%2FR%20AML%20patients%20with%20IDH2%20mutations%20can%20be%20salvaged%20by%20current%20treatments%20and%20benefit%20from%20prolonged%20survival.%20It%20is%20expected%20that%20novel%20targeted%20agents%20such%20as%20enasidenib%20will%20further%20improve%20efficacy%20and%20safety%20in%20the%20next%20future.%22%2C%22date%22%3A%22Apr%2027%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.leukres.2019.04.010%22%2C%22ISSN%22%3A%221873-5835%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A13Z%22%7D%7D%2C%7B%22key%22%3A%224TVVTHXC%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22De%20Barros%20et%20al.%22%2C%22parsedDate%22%3A%222019-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EDe%20Barros%2C%20Sandra%2C%20Flora%20Vayr%2C%20Fabien%20Despas%2C%20Mathilde%20Strumia%2C%20Cl%26%23xE9%3Bmentine%20Podevin%2C%20Martin%20Gauthier%2C%20Eric%20Delabesse%2C%20et%20al.%20%26%23x201C%3BThe%20Impact%20of%20Chronic%20Myeloid%20Leukemia%20on%20Employment%3A%20The%20French%20Prospective%20Study.%26%23x201D%3B%20%3Ci%3EAnnals%20of%20Hematology%3C%5C%2Fi%3E%2098%2C%20no.%203%20%28March%202019%29%3A%20615%26%23x2013%3B23.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00277-018-3549-5%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs00277-018-3549-5%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20impact%20of%20chronic%20myeloid%20leukemia%20on%20employment%3A%20the%20French%20prospective%20study%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sandra%22%2C%22lastName%22%3A%22De%20Barros%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Flora%22%2C%22lastName%22%3A%22Vayr%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabien%22%2C%22lastName%22%3A%22Despas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mathilde%22%2C%22lastName%22%3A%22Strumia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9mentine%22%2C%22lastName%22%3A%22Podevin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Gauthier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Marc%22%2C%22lastName%22%3A%22Soulat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Guy%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fabrice%22%2C%22lastName%22%3A%22Herin%22%7D%5D%2C%22abstractNote%22%3A%22Patients%20with%20chronic%20myeloid%20leukemia%20treated%20with%20breakpoint%20cluster%20region-Abelson%20tyrosine%20kinase%20inhibitors%20are%20likely%20to%20survive%20in%20excess%20of%2020%5Cu00a0years%20after%20diagnosis.%20New%20challenges%20appear%20as%20we%20consider%20life%20after%20the%20disease%2C%20including%20professional%20challenges%20and%20the%20social%20reintegration%20of%20patients.%20The%20purpose%20of%20this%20study%20was%20to%20determine%20the%20impact%20of%20chronic%20myeloid%20leukemia%20on%20employment%20within%202%5Cu00a0years%20after%20diagnosis.%20This%20prospective%2C%20observational%20study%20included%20patients%20diagnosed%20with%20chronic%20myeloid%20leukemia%20and%20treated%20with%20a%20tyrosine%20kinase%20inhibitor.%20Two%20populations%20were%20defined%20as%20patients%20who%20reported%20modifications%20in%20their%20professional%20activity%20during%20the%20study%20%28Acti-Pro%2B%29%20and%20patients%20who%20did%20not%20report%20a%20modification%20%28Acti-Pro-%29.%20Cancer%20survivors%20received%20a%20self-assessment%20questionnaire.%20The%20primary%20endpoint%20was%20to%20determine%20the%20professional%20status%20of%20patients.%20One%20hundred%20patients%20completed%20the%20questionnaire.%20Sixty-six%20patients%20out%20of%20100%20reported%20professional%20activity%20within%202%5Cu00a0years%20after%20their%20diagnosis.%20During%20the%202%5Cu00a0years%20after%20the%20diagnosis%2C%2065.2%25%20%2895%25%20confidence%20interval%20%28CI%29%2C%2053.7-76.7%29%20of%20patients%20faced%20modifications%20in%20their%20professional%20activity%20due%20to%20chronic%20myeloid%20leukemia%20or%20adverse%20effects%20of%20drug%20treatments%20%28group%20Acti-Pro%2B%29%3B%20in%20contrast%2C%2034.8%25%20of%20patients%20did%20not%20report%20any%20impact%20on%20their%20occupational%20activity%20%28group%20Acti-Pro-%29.%20Among%20modifications%20to%20work%20organization%2C%20a%20change%20in%20the%20number%20of%20working%20hours%20was%20the%20most%20represented.%20Other%20modifications%20comprised%20changes%20in%20status%20or%20work%20pace.%20A%20majority%20of%20chronic%20myeloid%20leukemia%20patients%20face%20professional%20consequences%20of%20their%20disease%20and%20treatments.%20Our%20findings%20suggest%20that%20adverse%20drug%20reactions%20are%20a%20major%20factor%20affecting%20the%20occurrence%20of%20work%20modifications%20in%20this%20context.%22%2C%22date%22%3A%22Mar%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs00277-018-3549-5%22%2C%22ISSN%22%3A%221432-0584%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-07-22T11%3A26%3A37Z%22%7D%7D%2C%7B%22key%22%3A%223ZTSUBD9%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Bertoli%20et%20al.%22%2C%22parsedDate%22%3A%222019-02%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EBertoli%2C%20Sarah%2C%20Etienne%20Paubelle%2C%20Emilie%20B%26%23xE9%3Brard%2C%20Estelle%20Saland%2C%20Xavier%20Thomas%2C%20Suzanne%20Tavitian%2C%20Marie-Virginie%20Larcher%2C%20et%20al.%20%26%23x201C%3BFerritin%20Heavy%5C%2FLight%20Chain%20%28FTH1%5C%2FFTL%29%20Expression%2C%20Serum%20Ferritin%20Levels%2C%20and%20Their%20Functional%20as%20Well%20as%20Prognostic%20Roles%20in%20Acute%20Myeloid%20Leukemia.%26%23x201D%3B%20%3Ci%3EEuropean%20Journal%20of%20Haematology%3C%5C%2Fi%3E%20102%2C%20no.%202%20%28February%202019%29%3A%20131%26%23x2013%3B42.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13183%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fejh.13183%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Ferritin%20heavy%5C%2Flight%20chain%20%28FTH1%5C%2FFTL%29%20expression%2C%20serum%20ferritin%20levels%2C%20and%20their%20functional%20as%20well%20as%20prognostic%20roles%20in%20acute%20myeloid%20leukemia%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sarah%22%2C%22lastName%22%3A%22Bertoli%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Paubelle%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emilie%22%2C%22lastName%22%3A%22B%5Cu00e9rard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Saland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suzanne%22%2C%22lastName%22%3A%22Tavitian%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Virginie%22%2C%22lastName%22%3A%22Larcher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Vergez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Audrey%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7oise%22%2C%22lastName%22%3A%22Huguet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cl%5Cu00e9ment%22%2C%22lastName%22%3A%22Larrue%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Claudie%22%2C%22lastName%22%3A%22Bosc%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Farge%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20Emmanuel%22%2C%22lastName%22%3A%22Sarry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mauricette%22%2C%22lastName%22%3A%22Michallet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%22%2C%22lastName%22%3A%22R%5Cu00e9cher%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVES%3A%20We%20previously%20reported%20the%20prognostic%20value%20of%20serum%20ferritin%20in%20younger%20patients%20with%20intermediate-risk%20acute%20myeloid%20leukemia%20%28AML%29.%20The%20aims%20of%20this%20study%20were%20to%20confirm%20this%20finding%20in%20a%20larger%20cohort%20regardless%20of%20age%20and%20prognostic%20subgroups%2C%20to%20explore%20the%20expression%20and%20functional%20role%20of%20ferritin%20in%20AML%20cells%20as%20well%20as%20the%20regulation%20of%20serum%20ferritin%20levels%20in%20AML%20patients.%5CnPATIENTS%5C%2FMATERIALS%5C%2FMETHODS%3A%20Serum%20ferritin%20levels%20at%20diagnosis%20were%20collected%20in%20a%20cohort%20of%20525%20patients%20treated%20by%20intensive%20chemotherapy.%20In%20silico%2C%20in%20vitro%2C%20and%20in%20vivo%20analyses%20were%20conducted%20to%20assess%20the%20pattern%20of%20expression%20and%20functional%20role%20of%20FTH1%20and%20FTL%20in%20AML.%5CnRESULTS%3A%20We%20confirmed%20the%20independent%20prognostic%20value%20of%20serum%20ferritin.%20In%20transcriptomic%20databases%2C%20FTH1%20and%20FTL%20were%20overexpressed%20in%20AML%20and%20leukemic%20stem%20cells%20compared%20to%20normal%20hematopoietic%20stem%20cells.%20The%20gene%20signature%20designed%20from%20AML%20patients%20overexpressing%20FTH1%20revealed%20a%20significant%20enrichment%20in%20genes%20of%20the%20immune%20and%20inflammatory%20response%20including%20Nf-KB%20pathway%2C%20oxidative%20stress%2C%20or%20iron%20pathways.%20This%20gene%20signature%20was%20enriched%20in%20cytarabine-resistant%20AML%20cells%20in%20a%20patient-derived%20xenograft%20model.%20FTH1%20protein%20was%20also%20overexpressed%20in%20patient%27s%20samples%20and%20correlated%20with%20the%20in%20vitro%20cytotoxic%20activity%20of%20cytarabine.%20Lastly%2C%20we%20demonstrated%20that%20chemotherapy%20induced%20an%20inflammatory%20response%20including%20a%20significant%20increase%20in%20serum%20ferritin%20levels%20between%20day%201%20and%208%20of%20induction%20chemotherapy%20that%20was%20blocked%20by%20dexamethasone.%5CnCONCLUSION%3A%20Ferritin%20is%20deregulated%20in%20most%20AML%20patients%20likely%20through%20inflammation%2C%20associated%20with%20chemoresistance%2C%20and%20could%20represent%20a%20new%20therapeutic%20target.%22%2C%22date%22%3A%22Feb%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fejh.13183%22%2C%22ISSN%22%3A%221600-0609%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228HPIVX5A%22%2C%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A42%3A25Z%22%7D%7D%2C%7B%22key%22%3A%22QPLEIFUK%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Passet%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EPasset%2C%20Marie%2C%20Nicolas%20Boissel%2C%20Fran%26%23xE7%3Bois%20Sigaux%2C%20Colombe%20Saillard%2C%20Mario%20Bargetzi%2C%20Ibrahima%20Ba%2C%20Xavier%20Thomas%2C%20et%20al.%20%26%23x201C%3BPAX5%20P80R%20Mutation%20Identifies%20a%20Novel%20Subtype%20of%20B-Cell%20Precursor%20Acute%20Lymphoblastic%20Leukemia%20with%20Favorable%20Outcome.%26%23x201D%3B%20%3Ci%3EBlood%3C%5C%2Fi%3E%20133%2C%20no.%203%20%2817%202019%29%3A%20280%26%23x2013%3B84.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2018-10-882142%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1182%5C%2Fblood-2018-10-882142%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22PAX5%20P80R%20mutation%20identifies%20a%20novel%20subtype%20of%20B-cell%20precursor%20acute%20lymphoblastic%20leukemia%20with%20favorable%20outcome%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Passet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Boissel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Fran%5Cu00e7ois%22%2C%22lastName%22%3A%22Sigaux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Colombe%22%2C%22lastName%22%3A%22Saillard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mario%22%2C%22lastName%22%3A%22Bargetzi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ibrahima%22%2C%22lastName%22%3A%22Ba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xavier%22%2C%22lastName%22%3A%22Thomas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Carlos%22%2C%22lastName%22%3A%22Graux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yves%22%2C%22lastName%22%3A%22Chalandon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thibaut%22%2C%22lastName%22%3A%22Leguay%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Etienne%22%2C%22lastName%22%3A%22Lenglin%5Cu00e9%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Johanna%22%2C%22lastName%22%3A%22Konopacki%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samuel%22%2C%22lastName%22%3A%22Quentin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Lafage-Pochitaloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22C%5Cu00e9dric%22%2C%22lastName%22%3A%22Pastoret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Grardel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vahid%22%2C%22lastName%22%3A%22Asnafi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22V%5Cu00e9ronique%22%2C%22lastName%22%3A%22Lh%5Cu00e9ritier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%22%2C%22lastName%22%3A%22Soulier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Herv%5Cu00e9%22%2C%22lastName%22%3A%22Dombret%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Clappier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22Group%20for%20Research%20on%20Adult%20ALL%20%28GRAALL%29%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%2201%2017%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1182%5C%2Fblood-2018-10-882142%22%2C%22ISSN%22%3A%221528-0020%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-10-11T11%3A45%3A31Z%22%7D%7D%2C%7B%22key%22%3A%22RIG233DF%22%2C%22library%22%3A%7B%22id%22%3A7813506%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Fournier%20et%20al.%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EFournier%2C%20Benjamin%2C%20Estelle%20Balducci%2C%20Nicolas%20Duployez%2C%20Emmanuelle%20Clappier%2C%20Wendy%20Cuccuini%2C%20Chlo%26%23xE9%3B%20Arfeuille%2C%20Aur%26%23xE9%3Blie%20Caye-Eude%2C%20et%20al.%20%26%23x201C%3BB-ALL%20With%20t%285%3B14%29%28Q31%3BQ32%29%3B%20IGH-IL3%20Rearrangement%20and%20Eosinophilia%3A%20A%20Comprehensive%20Analysis%20of%20a%20Peculiar%20IGH-Rearranged%20B-ALL.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Oncology%3C%5C%2Fi%3E%209%20%282019%29%3A%201374.%20%3Ca%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2019.01374%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffonc.2019.01374%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22B-ALL%20With%20t%285%3B14%29%28q31%3Bq32%29%3B%20IGH-IL3%20Rearrangement%20and%20Eosinophilia%3A%20A%20Comprehensive%20Analysis%20of%20a%20Peculiar%20IGH-Rearranged%20B-ALL%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Benjamin%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Estelle%22%2C%22lastName%22%3A%22Balducci%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nicolas%22%2C%22lastName%22%3A%22Duployez%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emmanuelle%22%2C%22lastName%22%3A%22Clappier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Wendy%22%2C%22lastName%22%3A%22Cuccuini%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chlo%5Cu00e9%22%2C%22lastName%22%3A%22Arfeuille%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Caye-Eude%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Eric%22%2C%22lastName%22%3A%22Delabesse%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elodie%22%2C%22lastName%22%3A%22Bottollier-Lemallaz%20Colomb%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karin%22%2C%22lastName%22%3A%22Nebral%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie-Lorraine%22%2C%22lastName%22%3A%22Chr%5Cu00e9tien%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Coralie%22%2C%22lastName%22%3A%22Derrieux%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aur%5Cu00e9lie%22%2C%22lastName%22%3A%22Cabannes-Hamy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Florent%22%2C%22lastName%22%3A%22Dumezy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pascaline%22%2C%22lastName%22%3A%22Etancelin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Odile%22%2C%22lastName%22%3A%22Fenneteau%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jamile%22%2C%22lastName%22%3A%22Frayfer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antoine%22%2C%22lastName%22%3A%22Gourmel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marie%22%2C%22lastName%22%3A%22Loosveld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22G%5Cu00e9rard%22%2C%22lastName%22%3A%22Michel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nathalie%22%2C%22lastName%22%3A%22Nadal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dominique%22%2C%22lastName%22%3A%22Penther%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Isabelle%22%2C%22lastName%22%3A%22Tigaud%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elise%22%2C%22lastName%22%3A%22Fournier%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bettina%22%2C%22lastName%22%3A%22Reism%5Cu00fcller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andishe%22%2C%22lastName%22%3A%22Attarbaschi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marina%22%2C%22lastName%22%3A%22Lafage-Pochitaloff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andr%5Cu00e9%22%2C%22lastName%22%3A%22Baruchel%22%7D%5D%2C%22abstractNote%22%3A%22Background%3A%20B-cell%20acute%20lymphoblastic%20leukemia%20associated%20with%20t%285%3B14%29%28q31%3Bq32%29%3B%20IGH-IL3%20is%20an%20exceptional%20cause%20of%20eosinophilia.%20The%20IGH%20enhancer%20on%2014q32%20is%20juxtaposed%20to%20the%20IL3%20gene%20on%205q31%2C%20leading%20to%20interleukin-3%20overproduction%20and%20release%20of%20mature%20eosinophils%20in%20the%20blood.%20Clinical%2C%20biological%20and%20outcome%20data%20are%20extremely%20scarce%20in%20the%20literature.%20Except%20for%20eosinophilia%2C%20no%20relevant%20common%20feature%20has%20been%20highlighted%20in%20these%20patients.%20However%2C%20it%20has%20been%20classified%20as%20a%20distinct%20entity%20in%20the%20World%20Health%20Organization%20classification.%20Cases%20Presentation%3A%20Eight%20patients%20with%20t%285%3B14%29%28q31%3Bq32%29%20treated%20by%20French%20or%20Austrian%20protocols%20were%20retrospectively%20enrolled.%20Array%20comparative%20genomic%20hybridization%2C%20multiplex%20ligation-dependent%20probe%20amplification%20or%20genomic%20PCR%20search%20for%20IKZF1%20deletion%20were%20performed%20in%207.%20Sixteen%20patients%20found%20through%20an%20exhaustive%20search%20in%20the%20literature%20were%20also%20analyzed.%20For%20those%2024%20patients%2C%20median%20age%20at%20diagnosis%20is%2014.3%20years%20with%20a%20male%20predominance%20%28male%20to%20female%20ratio%20%3D%205%29.%20Eosinophilia-related%20symptoms%20are%20common%20%28neurologic%20in%2026%25%2C%20thromboembolic%20in%2026%25%20or%20pulmonary%20in%2050%25%29.%20Median%20white%20blood%20cells%20count%20is%20high%20%2872%20%5Cu00d7%20109%5C%2FL%29%20and%20linked%20to%20eosinophilia%20%28median%3A%2032%20%5Cu00d7%20109%5C%2FL%29.%20Peripheral%20blasts%20are%20present%20at%20a%20low%20level%20or%20absent%20%28median%3A%200%20%5Cu00d7%20109%5C%2FL%3B%20range%3A%200-37%20%5Cu00d7%20109%5C%2FL%29.%20Bone%20marrow%20morphology%20is%20marked%20by%20a%20low%20blast%20infiltration%20%28median%3A%2042%25%29.%20We%20found%20an%20IKZF1%20deletion%20in%205%20out%20of%207%20analyzable%20patients%20Outcome%20data%20are%20available%20for%2014%20patients%20%28median%20follow-up%3A%2028%20months%29%3A%208%20died%20and%206%20are%20alive%20in%20complete%20remission.%20Some%20of%20these%20features%20are%20concordant%20with%20those%20seen%20in%20patients%20with%20other%20IGH-rearranged%20B-cell%20acute%20lymphoblastic%20leukemias%3A%20young%20age%20at%20onset%2C%20male%20sex%2C%20low%20blast%20count%2C%20high%20incidence%20of%20IKZF1%20deletion%20and%20intermediate%20prognosis.%20Conclusion%3A%20Based%20on%20shared%20epidemiological%20and%20biological%20features%2C%20B-cell%20acute%20lymphoblastic%20leukemia%20with%20t%285%3B14%29%28q31%3Bq32%29%20is%20a%20peculiar%20subset%20of%20IGH-rearranged%20B-cell%20acute%20lymphoblastic%20leukemia%20with%20an%20intermediate%20prognosis%20and%20particular%20clinical%20features%20related%20to%20eosinophilia.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.3389%5C%2Ffonc.2019.01374%22%2C%22ISSN%22%3A%222234-943X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229RREECEZ%22%5D%2C%22dateModified%22%3A%222021-04-26T15%3A23%3A55Z%22%7D%7D%5D%7D<\/span>\n\n\t\t\t\t
\n
\n
Péricart, Sarah, Charlotte Waysse, Aurore Siegfried, Stephanie Struski, Eric Delabesse, Camille Laurent, and Solène Evrard. “Subsequent Development of Histiocytic Sarcoma and Follicular Lymphoma: Cytogenetics and next-Generation Sequencing Analyses Provide Evidence for Transdifferentiation of Early Common Lymphoid Precursor-a Case Report and Review of Literature.” Virchows Archiv: An International Journal of Pathology<\/i>, December 5, 2019. https:\/\/doi.org\/10.1007\/s00428-019-02691-w<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Lopez, Cecile K., Esteve Noguera, Vaia Stavropoulou, Elie Robert, Zakia Aid, Paola Ballerini, Chrystele Bilhou-Nabera, et al. “Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene-Driven Myeloid Leukemia.” Cancer Discovery<\/i>, October 29, 2019. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1463<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Largeaud, Laetitia, Sarah Bertoli, Emilie Bérard, Stéphanie Dufrechou, Naïs Prade, Noémie Gadaud, Suzanne Tavitian, et al. “Outcome of Relapsed\/Refractory AML Patients with IDH1R132 Mutations in Real Life before the Era of IDH1 Inhibitors.” Leukemia & Lymphoma<\/i>, September 30, 2019, 1–4. https:\/\/doi.org\/10.1080\/10428194.2019.1668937<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bertoli, Sarah, Suzanne Tavitian, Pierre Bories, Isabelle Luquet, Eric Delabesse, Thibault Comont, Audrey Sarry, Françoise Huguet, Emilie Bérard, and Christian Récher. “Outcome of Patients Aged 60-75 Years with Newly Diagnosed Secondary Acute Myeloid Leukemia: A Single-Institution Experience.” Cancer Medicine<\/i>, June 7, 2019. https:\/\/doi.org\/10.1002\/cam4.2020<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Comont, T., K. Delavigne, P. Cougoul, S. Bertoli, E. Delabesse, P. Fenaux, and O. Beyne-Rauzy. “[Management of myelodysplastic syndromes in 2019: An update].” La Revue De Medecine Interne<\/i>, May 1, 2019. https:\/\/doi.org\/10.1016\/j.revmed.2019.04.001<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Largeaud, Laetitia, Emilie Bérard, Sarah Bertoli, Stéphanie Dufrechou, Naïs Prade, Noémie Gadaud, Suzanne Tavitian, et al. “Outcome of AML Patients with IDH2 Mutations in Real World before the Era of IDH2 Inhibitors.” Leukemia Research<\/i> 81 (April 27, 2019): 82–87. https:\/\/doi.org\/10.1016\/j.leukres.2019.04.010<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
De Barros, Sandra, Flora Vayr, Fabien Despas, Mathilde Strumia, Clémentine Podevin, Martin Gauthier, Eric Delabesse, et al. “The Impact of Chronic Myeloid Leukemia on Employment: The French Prospective Study.” Annals of Hematology<\/i> 98, no. 3 (March 2019): 615–23. https:\/\/doi.org\/10.1007\/s00277-018-3549-5<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Bertoli, Sarah, Etienne Paubelle, Emilie Bérard, Estelle Saland, Xavier Thomas, Suzanne Tavitian, Marie-Virginie Larcher, et al. “Ferritin Heavy\/Light Chain (FTH1\/FTL) Expression, Serum Ferritin Levels, and Their Functional as Well as Prognostic Roles in Acute Myeloid Leukemia.” European Journal of Haematology<\/i> 102, no. 2 (February 2019): 131–42. https:\/\/doi.org\/10.1111\/ejh.13183<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Passet, Marie, Nicolas Boissel, François Sigaux, Colombe Saillard, Mario Bargetzi, Ibrahima Ba, Xavier Thomas, et al. “PAX5 P80R Mutation Identifies a Novel Subtype of B-Cell Precursor Acute Lymphoblastic Leukemia with Favorable Outcome.” Blood<\/i> 133, no. 3 (17 2019): 280–84. https:\/\/doi.org\/10.1182\/blood-2018-10-882142<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\t\t\t\t
\n
\n
Fournier, Benjamin, Estelle Balducci, Nicolas Duployez, Emmanuelle Clappier, Wendy Cuccuini, Chloé Arfeuille, Aurélie Caye-Eude, et al. “B-ALL With t(5;14)(Q31;Q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.” Frontiers in Oncology<\/i> 9 (2019): 1374. https:\/\/doi.org\/10.3389\/fonc.2019.01374<\/a>.<\/div>\n<\/div>\n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t<\/div>\n\n\n

[\/et_pb_toggle][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”448e09ae-9652-4ead-bc5f-152c7adf1202″ global_colors_info=”{}”]<\/p>\n

LES MEMBRES DE L\u2019\u00c9QUIPE<\/strong><\/h2>\n

[\/et_pb_text][et_pb_divider color=”#F19532″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_divider][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.16″ _module_preset=”default” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.16″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

\n
<\/div>\n\n\n
\n
\n
\n
\n
\n
\"\"<\/a><\/div>\n
J\u00e9r\u00e9my Bigot<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Justine Thomas<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Pauline Enfedaque<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Philippe Leleux<\/a><\/div>\n
Chercheur Post-Doctorant \/ Post-Doc researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Antoine Nouhaud<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Isabelle Luquet<\/a><\/div>\n
Clinicien Chercheur \/ Researcher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
La\u00ebtitia Largeaud<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Esmaa Sellam<\/a><\/div>\n
Doctorant \/ PhD student<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
St\u00e9phanie Dufr\u00e9chou<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Christine Didier<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Na\u00efs Prade<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Marl\u00e8ne Pasquet<\/a><\/div>\n
Enseignant chercheur \/ University researcher<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
St\u00e9phanie Struski<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Mathieu Bouttier<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Eric Delabesse<\/a><\/div>\n
Hospitalo-Universitaire \/ University teacher hospital practitioner<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Christel Lauer<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Cyril Broccardo<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Sylvie Hebrard<\/a><\/div>\n
Technicien de laboratoire \/ Laboratory Technician<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Bastien Gerby<\/a><\/div>\n
Chercheur statutaire \/ permanent scientist<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n
\n
\n
\"\"<\/a><\/div>\n
Camille Hamelle<\/a><\/div>\n
Ing\u00e9nieur de laboratoire \/ laboratory engineer<\/div><\/div>\n<\/div><\/div><\/div> <\/div>\n <\/div>\n<\/div><\/div>\n\n
\n
<\/div>\n